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Abstract.
Introduction: Identification of blood-based metabolic changes might provide
early and easy-to-obtain biomarkers.
Methods: We included 127 AD patients and 121 controls with CSF-biomarker-
confirmed diagnosis (cut-off tau/Aβ42: 0.52). Mass spectrometry platforms
determined the concentrations of 53 amine, 22 organic acid, 120 lipid, and
40 oxidative stress compounds. Multiple signatures were assessed: differen-
tial expression (nested linear models), classification (logistic regression), and
regulatory (network extraction).
Results: Twenty-six metabolites were differentially expressed. Metabolites im-
proved the classification performance of clinical variables from 74% to 79%.
Network models identified 5 hubs of metabolic dysregulation: Tyrosine, gly-
cylglycine, glutamine, lysophosphatic acid C18:2 and platelet activating factor
C16:0. The metabolite network for APOE 4 negative AD patients was less
cohesive compared to the network for APOE 4 positive AD patients.
Discussion: Multiple signatures point to various promising peripheral markers
for further validation. The network differences in AD patients according to
APOE genotype may reflect different pathways to AD.
Key words: Alzheimer’s disease; Amino acids; Biomarkers; Graphical model-
ing; Metabolomics; Oxidative stress
Abbreviations: 2-AAA = 2-aminoadipic acid; Aβ42 = Amyloid beta peptide
42; AD = Alzheimer’s disease; ADC = Amsterdam Dementia Cohort; APOE
= apolipoprotein E; AUC = Area Under the (Receiver Operating Characteris-
tic) Curve; BMI = body mass index; CI = confidence interval; CSF = cerebral
spinal fluid; DBP = diastolic blood pressure; DNA = deoxyribonucleic acid;
EDTA = ethylenediaminetetraacetic acid; FDR = false discovery rate; g =
Earth’s gravitational force; IQR = interquartile range; LPA = lysophosphatic
acid; PC = phosphatidylcholine; MAP = mean arterial pressure; MCI = mild
cognitive impairment; MS = mass spectrometry; NIA-AA = National Institute
of Aging and Alzheimer’s Association; PAF = platelet activating factor; ROC
= Receiver Operating Characteristic; RSDQC = relative standard deviation of
quality control; SBP = systolic blood pressure; SCD = subjective cognitive de-
cline; SD = standard deviation; SM = sphingomyelin SMT2 = Supplementary
Text 2; TG = triglyceride
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1. Introduction
Accumulation of amyloid and tau-protein are considered the core pathological
hallmarks for Alzheimer’s disease (AD) [1], but other factors such as genetic liability,
oxidative stress, inflammation and lifestyle contribute to the complex mechanism of
this disease [1, 2, 3, 4, 5]. Non-invasive measurement of disease-specific biochemical
changes in living patients is difficult, but may have value in terms of prognosis and
identification of patients at risk for AD.
The metabolome, i.e., the collection of small-molecules that result from meta-
bolic processes, is organized in biochemical pathways and is influenced by many
internal and external factors, including genetics [6]. Metabolomics refers to the col-
lective quantification of these metabolites [7]. Analytical methods have improved
tremendously, with (targeted) mass spectrometry (MS) platforms now available for
most compound classes. In AD, metabolomics seems of utmost importance since
various alterations in metabolism, e.g., higher levels of insulin and insulin resistance,
are associated with an increased risk of AD [8]. Moreover, the epsilon 4 (4) allele
of the apolipoprotein E (APOE ) gene is not only an important risk-factor for AD
but is also related to alterations in lipid metabolism [9, 10]. Previous metabolomics
studies in AD have reported alterations in lipid, antioxidant and amino acid me-
tabolism. However, results are not always unequivocal [11, 12, 13, 14, 15]. This is
most likely due to differences in (analytical) methods, cohort selection or context
of use [16].
We aim to study AD-related metabolic change from various perspectives with
the use of multiple signatures in order to generate hypotheses regarding dysreg-
ulated metabolic events. First, we evaluate shifts in the expression of individual
metabolites using nested linear models. Afterwards, we assess the classification
performance of the metabolites in demarcating AD from control subjects. Finally,
we use state-of-the-art graphical modeling to explore metabolic dysregulation from
a network perspective. Additionally, we evaluate metabolic network changes ac-
cording to APOE status, to study the hypothesis that metabolic pathways are
differentially dysregulated according to genotype.
2. Methods
2.1. Patients. We selected 150 AD patients and 150 controls with available
plasma from the Amsterdam Dementia Cohort (ADC) [17]. All subjects under-
went standard cognitive screening including medical history assessment, physical-,
neurological- and cognitive examination, blood sampling, lumbar puncturing, and
magnetic resonance imaging. Diagnoses were made in a multidisciplinary consen-
sus meeting. Until 2012, the diagnosis ‘probable AD’ was based on the clinical
criteria formulated by the NINCDS-ADRDA (National Institute of Neurological
and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association) [18]. From 2012 onwards the criteria of the NIA-AA (Na-
tional Institute on Aging-Alzheimer’s Association) were used [19]. Subjects with
subjective cognitive decline (SCD) were used as controls. These subjects presented
with memory complaints at the VUmc memory clinic, but performed normal on
cognitive testing, i.e., criteria for mild cognitive impairment (MCI), dementia or
psychiatric diagnosis were not fulfilled. Clinical characteristics are provided in Ta-
ble 1. All subjects gave written informed consent to use their clinical data for
research purposes and to collect their blood samples for biobanking.
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2.2. CSF Biomarkers. Amyloid beta peptide 42 (Aβ42) and total tau (t-tau)
were, for all subjects, measured in cerebrospinal fluid (CSF) using commercially
available enzyme-linked immunosorbent assays (Innotest Aβ42 and Innotest hTAU-
Ag; Innogenetics, Ghent, Belgium) [20]. The cut-off for pathological biomarker
status was defined as t-tau/Aβ42 > 0.52 [21]. Of the 300 subjects included, 263
(136 AD patients and 127 controls) had a biomarker status in concordance with
their clinical diagnosis, i.e., t-tau/Aβ42 > 0.52 for AD and t-tau/Aβ42 ≤ 0.52 for
controls. These subjects were included for further analysis.
2.3. APOE Genotyping. Deoxyribonucleic acid (DNA) was isolated from 7-10ml
EDTA blood. Subsequently, samples were subjected to polymerase chain reaction.
A QIAxcel DNA Fast Analysis kit (Qiagen c©, Venlo, The Netherlands) was used to
check for size. Sequencing was performed using Sanger sequencing on an ABI130XL.
2.4. Metabolic Profiling. Non-fasting EDTA plasma samples were, within 2
hours of collection, centrifuged at 1800×g for 10 minutes by room temperature and
stored at −80◦C in polypropylene tubes (Sarstedt, Nurmberg, Germany). Meta-
bolic profiling of the samples was performed on four mass spectrometry (MS) plat-
forms; i.e., amines, lipids and oxidative stress compounds were identified using
ultra-performance liquid chromatography-tandem MS, and organic acids were an-
alyzed with gas chromatography-MS [7, 22, 23, 24]. Reproducibility of individual
metabolites was assessed in terms of the relative standard deviation of quality
control (RSDQC) samples. Metabolites with RSDQC > 30% were deemed to fail
acceptance criteria. After QC correction, 53 amine compounds, 22 organic acid
compounds, 120 lipid compounds, and 40 oxidative stress compounds were consid-
ered detected. See Supplementary Text 1 and its accompanying tables for details
on the profiling methods and detected compounds.
2.5. Data Processing. Metabolites with more than 10% missing observations
were removed, leading to the removal of 4 lipid compounds and 1 oxidative stress
compound. Three data samples (i.e., observed metabolite abundance profiles stem-
ming from corresponding plasma samples) were removed as their (plasma) quality
was deemed unsure. These samples had many (30 or more) concentrations below
the limit of detection (LOD) that could not be attributed to instrumental errors.
Twelve additional data samples were removed due to instrumental errors in one or
more platforms. Hence, we only retained data samples that were free of instrumen-
tal errors across all four different MS platforms. The remaining missing values are
attributable to concentrations failing the LOD. These (feature-specific) missing val-
ues were imputed by half of the lowest observed value (for the corresponding meta-
bolic feature). The final metabolic data set thus contained n = 263− 3− 12 = 248
data samples (127 AD patients and 121 controls) and p = 235−5 = 230 metabolites.
The possible confounding effects of the clinical characteristics regarding anthro-
pometrics, intoxications, comorbidities, and medication were evaluated in the ex-
pression and classification signatures demarcating the AD and control groups (see
Section 2.6). Table 1 contains the full list of characteristics and Table S2.1 of Sup-
plementary Text 2 (SMT2) contains additional information on measurement. The
missing observations on these variables (< 6%) were imputed. Continuous vari-
ables were imputed on the basis of Bayesian linear regression, polytomous variables
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were imputed on the basis of polytomous regression, and binary variables were im-
puted on the basis of logistic regression [25]. See Section 1 of SMT2 for additional
information on data processing.
2.6. Statistical Analysis. Differences in clinical characteristics between AD pa-
tients and controls were evaluated through Chi-square, Mann-Whitney U, and t-
testing. Differential metabolic expression between AD patients and controls was
assessed by using nested linear models. We tested, for each individual metabolite,
whether its addition to a model containing clinical characteristics significantly con-
tributed to model fit. One then assesses if, conditional on the effects of the clinical
characteristics, metabolic expression does indeed differ between the AD and con-
trol groups. This entails an F -test for nested models (see Section 2.1 of SMT2 for
details). The conditioning sets were (i) sex and age, and (ii) all clinical charac-
teristics. We adjusted for multiple testing by controlling the False Discovery Rate
(FDR) [26] at .05.
Subsequently, metabolic classification signatures for the prediction of group
membership (AD or control) were constructed by way of penalized logistic regres-
sion with a Lasso-penalty [27]. The Lasso-penalty enables estimation in our setting
where the metabolite to sample ratio (230/248) is too high for standard logistic
regression. It also achieves automatic feature selection. Two settings were consid-
ered: (i) the Lasso selects among the metabolites without considering the clinical
characteristics; and (ii) the Lasso selects among the metabolites while the clinical
characteristics go unpenalized. The resulting models were compared to an unpe-
nalized logistic regression model that considered only the clinical characteristics.
The optimal penalty parameter in the penalized models was determined on the ba-
sis of leave-one-out cross-validation (LOOCV) of the model likelihood. Predictive
performance of all models was assessed by way of (the comparison of) Receiver
Operating Characteristic (ROC) curves and Area Under the ROC Curves (AUCs).
ROC curves and AUCs for all models were produced by 10-fold cross-validation.
See Section 2.2 of SMT2 for additional information.
A metabolic pathway can be thought of as a collection of metabolites originating
from all over the metabolome, that work interdependently to regulate biochemical
(disease) processes. Hence, a pathway is a network. We additionally employed
network extraction techniques to examine regulatory signatures, i.e., dysregulation
in metabolic biochemical pathways pertaining to the AD disease process. From
a network perspective, molecular pathway-dysregulation is likely characterized by
the loss of normal (wanted) molecular interactions and the gain of abnormal (un-
wanted) molecular interactions. From this perspective, the network topologies of
the AD and control groups are expected to primarily share the same structure,
while potentially differing in a number of (topological) locations of interest. Net-
work extraction was based on graphical modeling, more specifically, on targeted
fused ridge estimation of inverse covariance (i.e., scaled partial correlation) matri-
ces [28]. This method (i) can deal with our metabolite to sample ratio (230/248,
which is too high for standard graphical modeling), and (ii) explicitly takes into
account that there are multiple groups of interest for which the shared network
structures should be fused while the unique network structures should be distin-
guished. The resulting networks are to be interpreted as conditional independence
graphs, i.e, the nodes represent metabolic compounds and the edges connecting
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the nodes represent substantive partial correlations. Extracted networks were sub-
jected to subsequent analyses aimed at detecting hub compounds, group structures,
and differential metabolic connections between groupings of interest. Our efforts
first juxtaposed metabolic networks for AD patients and controls. Subsequently,
we compared networks according to APOE genotype. See Sections 2.3 and 2.4 of
SMT2 for additional detail.
3. Results
3.1. Clinical Characteristics. Table 1 contains an overview of the clinical char-
acteristics per diagnostic group. The Mini-Mental State Examination (MMSE)
score [29] of AD patients was lower compared to controls. AD patients were more
often carrier of at least 1 APOE 4 allele. Moreover, AD patients had a lower BMI
and were less likely to have diabetes.
3.2. Differential Expression Signature. A global test [30] indicates that, given
sex and age, the overall metabolic expression profile differs between AD patients
and controls (p = 2.12× 10−6). This difference in overall metabolic expression
profile upholds when correcting for all clinical characteristics (p = 4.69× 10−5).
The metabolites listed in Table 2 pass multiple testing correction on the F -test
for nested models (Section 2.6) with an FDR < .05. The third column gives the
Table 1. Comparison clinical characteristics between AD and con-
trol groups.
Characteristic AD group Control group p-value
n(%) 127 (51) 121 (49)
MMSE score, median (IQR) 21 (5.5) 29 (2) < .001∗
Anthropometric:
Age, median (IQR) 65.1 (9.1) 62.7 (8) .548∗
Gender (female), n(%) 63 (50) 56 (46) .692†
≥ 1 APOE 4 allele (yes), n(%) 87 (69) 34 (28) < .001†
MAP, mean (SD) 106.1 (11.5) 103.9 (11.7) .133‡
BMI, mean (SD) 24.2 (3.3) 26.27 (3.6) < .001‡
Intoxications:
Smoking .558†
Former, n(%) 42 (33) 46 (38)
Current, n(%) 21 (17) 15 (12)
Alcohol (yes), n(%) 98 (77) 88 (73) .509†
Comorbidities:
Hypertension (yes), n(%) 37 (29) 33 (27) .854†
Diabetes Mellitus (yes), n(%) 4 (3) 14 (12) .021†
Hypercholesterolemia (yes), n(%) 14 (11) 9 (7) .451†
Medication:
Cholesterol lowering (yes), n(%) 31 (24) 22 (18) .298†
Antidepressants (yes), n(%) 12 (9) 15 (12) .589†
Antiplatelets (yes), n(%) 26 (20) 19 (16) .418†
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body
mass index; IQR, interquartile range; MAP, mean arterial pressure; MMSE, Mini-
Mental State Examination; SD, standard deviation.
* Mann-Whitney U test.
† Pearson χ2 test.
‡ Welch’s t test.
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ranking (in terms of raw p-value) of 52 metabolites that survive FDR correction
when adjusting for sex and age only. The fourth column analogously ranks the
26 metabolites that survive FDR correction when additionally adjusting for all
clinical characteristics. Triglycerides and amines dominate the latter compounds
list. Among its top compounds, in terms of (adjusted) p-value, are the amines 2-
aminoadipic acid (2-AAA) and Tyrosine, the triglyceride TG(51:3), and the organic
acid 3-Hydroxyisovaleric acid. Their distributions in the AD and control groups are
depicted in Figure 1. We see that these compounds are underexpressed in the AD
group relative to the control group. This relative underexpression in the AD group
also holds for the remaining compounds in column 4 of Table 2, except for the
Sphingomyelin SM(d18:1/20:1), which is overexpressed in the AD group relative to
the control group (see Figures S2.1, S2.2, and S2.3 in SMT2 ).
Figure 1. Violin plots of the top 4 metabolites in terms of p-value. Violin
plots [31] combine the familiar box plot with a kernel density to better represent
the distribution of the data. We see relative underexpression in the AD group
for all depicted metabolites. The associated adjusted p-values can be found in
Table 2. The violin plots of the remaining differentially expressed metabolites
can be found in Figures S2.1, S2.2, and S2.3 of SMT2.
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Table 2. Differentially expressed metabolites that survive FDR
adjustment. The third column ranks (in terms of raw p-value) the
metabolites that survive FDR correction in the model that adjusts
for sex and age only. The fourth column ranks (in terms of raw
p-value) the metabolites that survive FDR correction in the model
that adjusts for all clinical characteristics. See Tables 2.2 and 2.3
of SMT2 for additional information.
Metabolite Compound class Ranking
2-Aminoadipic acid Amines 1 1
Valine Amines 2 16
Tyrosine Amines 3 4
Methyldopa Amines 4 9
Lysine Amines 5
Methylmalonic acid Organic acids 6 14
S-3-Hydroxyisobutyric acid Organic acids 7 7
TG(48:0) Lipids: Triglycerides 8 21
TG(50:4) Lipids: Triglycerides 9 6
TG(48:2) Lipids: Triglycerides 10 13
TG(51:3) Lipids: Triglycerides 11 2
TG(54:6) Lipids: Triglycerides 12 5
TG(50:3) Lipids: Triglycerides 13 17
TG(50:2) Lipids: Triglycerides 14
TG(50:1) Lipids: Triglycerides 15
TG(48:1) Lipids: Triglycerides 16 25
TG(52:4) Lipids: Triglycerides 17 18
TG(48:3) Lipids: Triglycerides 18 11
Leucine Amines 19
LPC(18:1) Lipids: Lysophosphatidylcholine 20
TG(46:2) Lipids: Triglycerides 21 15
TG(50:0) Lipids: Triglycerides 22
TG(52:5) Lipids: Triglycerides 23 19
TG(52:3) Lipids: Triglycerides 24
TG(51:2) Lipids: Triglycerides 25
TG(56:8) Lipids: Triglycerides 26 8
Isoleucine Amines 27
2-hydroxybutyric acid Organic acids 28
3-Hydroxyisovaleric acid Organic acids 29 3
TG(51:1) Lipids: Triglycerides 30
SM(d18:1/20:1) Lipids: Sphingomyelins 31 24
TG(52:1) Lipids: Triglycerides 32
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane 33 10
Proline Amines 34
TG(54:5) Lipids: Triglycerides 35
TG(56:7) Lipids: Triglycerides 36 20
PGD2 Lipids: Prostaglandins 37
TG(46:1) Lipids: Triglycerides 38
PC(O-44:5) Lipids: Plasmalogen Phosphatidylcholine 39
LPA C14:0 Lyso-phosphatidic acid 40
PC(O-34:1) Lipids: Plasmalogen Phosphatidylcholine 41
LPC(20:4) Lipids: Lysophosphatidylcholine 42
SM(d18:1/24:2) Lipids: Sphingomyelins 43
8,12-iPF2a IV Oxidative stress: Isoprostane 44
TG(46:0) Lipids: Triglycerides 45
5-iPF2a VI Oxidative stress: Isoprostane 46
TG(52:2) Lipids: Triglycerides 47
SM(d18:1/16:0) Lipids: Sphingomyelins 48
TG(58:10) Lipids: Triglycerides 49 26
Ornithine Amines 50 22
Histidine Amines 51
O-Acetylserine Amines 12
SM(d18:1/23:0) Lipids: Sphingomyelins 23
3.3. Classification Signature. Subsequently, penalized logistic regression mod-
els were used to evaluate the ability of metabolites to distinguish AD patients from
controls. Classification performances can be found in Figure 2. The prediction
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model carrying the clinical variables only resulted in an AUC of approximately
.74 (95% bootstrap CI: .67 − .79). The model that used the Lasso for selection
amongst the metabolites sorts a comparable classification performance, yielding an
AUC of approximately .70 (95% bootstrap CI: .63 − .76). The added value of the
metabolites is reflected in the prediction model that adds a (Lasso-based) selection
of metabolites to the clinical variables as it improves predictive performance, sort-
ing a AUC of .79 (95% bootstrap CI: .73 − .84). A one-tailed bootstrap test for
correlated ROC curves [32] indicates that the AUC for this latter model is indeed
higher than the AUC for the metabolites-only model (p = .002) and the AUC for
the clinical-variables-only model (p = .005). This test also indicates that the AUCs
for the metabolites-only and clinical-variables-only models do not differ significantly
(p = .203). Metabolites consistently selected as top predictors (in terms of their
absolute regression coefficient) in both penalized models that also occur in the dif-
ferential expression signature are: the amines O-Acetylserine and Methyldopa, the
triglyceride TG(51:5), and the organic Methylmalonic acid. Furthermore, oxidative
stress compounds were selected by the Lasso on the basis of their predictive power,
especially the prostaglandin PGD2, the isoprostane 8,12-iPF2a IV, and the nitro-
fatty acid NO2-aLA (C18:3). See Tables S2.4 and S2.5 of SMT2 for additional
detail.
Figure 2. ROC curves for the classification models. The grey line repre-
sents the ROC curve for the unpenalized logistic regression model that enter-
tains the clinical characteristics only. The red line represents the ROC curve
for the logistic model in which the Lasso performed variable selection amongst
the metabolites (and that does not consider the clinical characteristics). The
blue line represents the ROC curve of the logistic model in which the clinical
characteristics are present while the Lasso may select amongst the metabolites.
The clinical variables are listed in Table 1.
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3.4. Regulatory Signature. Next, graphical modeling was used to explore
metabolite-networks. Section 2.3.3 of SMT2 contains visualizations of the ex-
tracted networks for AD patients and controls. These networks convey that the
strongest connections implicate metabolites from all four considered compound
classes. The metabolite-network for the control patients seems stronger locally
connected (Section 2.3.4 of SMT2 ), but both the AD and control networks are
cohesive in the sense that they can be decomposed into clear communities (groups)
of metabolites (Section 2.3.6 of SMT2 ). Hub compounds (i.e., metabolites of
high regulatory importance as indicated by their centrality in a network) concur
to some degree between the AD and control networks, with both having the Lyso-
phosphatidic acid (LPA) C18:2 (an oxidative stress compound) as the strongest hub.
In the AD network however, as opposed to the control network, the amines Gly-
cylglycine and Tyrosine are additionally indicated as central metabolites (Section
2.3.5 of SMT2 ). LPA C18:2, Glycylglycine and Tyrosine are amongst the metabo-
lites whose regulatory functioning (in terms of differential connections) seems to
change the most between the AD and control networks (Section 2.3.7 of SMT2 ).
Overall, the AD and control networks seem to imply a shifting importance to-
wards amine and oxidative stress compounds and their connections in the former.
This picture becomes more pronounced when the networks are stratified according
to APOE genotype (Section 2.4 of SMT2 ). Figure 3 contains visualizations of
the extracted networks for APOE 4 negative controls and AD patients as well as
APOE 4 positive controls and AD patients. The networks for APOE 4 positive
controls and APOE 4 negative AD patients seem more random and less cohe-
sive than the networks for APOE 4 negative controls and APOE 4 positive AD
patients. Comparing the cohesive networks for APOE 4 negative controls and
APOE 4 positive AD patients (Section 2.4 of SMT2 ) we see that all amines be-
long to the peripheral-structure in the former while many amines belong to the
core-structure in the latter. This might imply that biochemical functioning in the
APOE 4 positive AD group is more reliant on amines. Hub compounds concur
to some degree between these networks, with again (o.a.) LPA C18:2 as a strong
hub. In the network for APOE 4 positive AD patients the amines Glycylglycine
and Tyrosine are consistently indicated as central metabolites. Figure 4 presents
the networks of shared and differential connections between the APOE 4 negative
control and APOE 4 positive AD groups. The oxidative stress compounds LPA
C18:2 and platelet activating factor (PAF) C16:0, and the amines Glycylglycine,
Tyrosine, and Glutamine seem to change their regulatory function the most be-
tween the APOE 4 negative control and APOE 4 positive AD groups (also see
Table S2.12 in SMT2 ). From the network perspective the APOE 4-driven AD
state can be characterized (vis-a`-vis the control state without APOE 4 alleles) by
a loss of connections involving PAF C16:0, a gain of connections involving Gly-
cylglycine, and the differential wiring (both loss of normal and gain of alternative
connections) of Tyrosine, Glutamine, and LPA C18:2.
3.5. CSF Discordant Subjects. Subjects whose clinical diagnosis was discor-
dant from their CSF-biomarker status have an insecure disease status and where
therefore excluded from the analyzes above. A total of 37 subjects had both a
complete metabolite-profile and a discordant CSF-biomarker status. That is, these
subjects were either clinically diagnosed with AD while their CSF-markers were
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normal (t-tau/Aβ42 ≤ 0.52) or clinically diagnosed as normal while their CSF-
markers indicated AD (t-tau/Aβ42 > 0.52). For purposes of comparison we also
obtained the expression and classification signatures when considering data from
all n = 285 (263 + 37) subjects with a complete metabolite-profile. The results –
that accede to some degree with the results given in Sections 3.2 and 3.3 above –
can be found (with discussion) in Supplementary Text 3.
Figure 3. Class-specific networks visualized with the Fruchterman-
Reingold [33] algorithm. The upper-left panel contains the network for the
control group with no APOE 4 allele. The upper-right panel contains the
network for the control group with at least 1 APOE 4 allele. The lower-
left panel represents the network for the AD group with no APOE 4 allele.
The lower-right panel represents the network for the AD group with at least 1
APOE 4 allele. The metabolite compounds are colored according to metabo-
lite family: Blue for amines, yellow for lipids, orange for organic acids, and
purple for oxidative stress. Solid edges represent positive partial correlations
while dashed edges represent negative partial correlations.
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Figure 4. Common and differential networks for the control group with no APOE 4 allele versus the AD group with at least 1 APOE
4 allele. The left-hand panel contains the network consisting of the edges (solid and colored blue) that are shared between these groups.
The right-hand panel contains the network consisting of the edges that are unique for either of the groups. Red edges represent connections
that are present in the APOE 4 positive AD group only. Green edges represent connections that are present in the APOE 4 negative
control group only. Solid edges represent positive partial correlations while dashed edges represent negative partial correlations. The
metabolite compounds are colored according to metabolite family: Blue for amines, yellow for lipids, orange for organic acids, and purple
for oxidative stress.
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4. Discussion
In this study, with CSF-biomarker-confirmed AD and control cases, we show
that profiling metabolic alterations in AD can highlight disease-specific biochemi-
cal changes. We assessed three metabolic signatures to highlight different aspects
of metabolic change. The expression signature shows the metabolites with rela-
tive under- or overexpression in AD versus controls. This signature involved 26
metabolites, dominated by decreased levels of triglycerides and amines in AD. We
then evaluated classification signatures: collections of clinical and metabolite mark-
ers that can successfully demarcate AD cases from controls. The top predictors
concur (also in their sign) with metabolites found in the differential expression
signature. In addition, markers of oxidative stress were identified as strong predic-
tors. Lastly, graphical modeling was employed to evaluate regulatory signatures:
exploratory networks of complex differential metabolite-dependencies between the
AD and control groups. Possible regulatory markers were again found in the amine
and oxidative stress compound classes. Stratifying for APOE 4 status, the net-
work for APOE 4 negative AD subjects was less cohesive compared to the net-
work for APOE 4 positive AD subjects. This suggests alternative biochemical-
dysregulation involved in these patient groups. Each signature gives a different but
complementary perspective on AD-related metabolic events. We propose the com-
bination of these three signatures as a new approach to (i) studying the complex
mechanism of metabolic change, (ii) defining characteristics involved in subtypes
of AD, and (iii) selecting robust markers of interest for further research. Below, we
discuss and embed the findings related to each signature.
4.1. Differential Expression Signature. We show in Table 2 that additional
adjustments for clinical characteristics shortens the list and changes the ranking
of metabolites that survive FDR correction. This underlines the effects of clinical
variables, such as medication, on the metabolome. It also suggests that substan-
tive corrections harness against overoptimistic expression signatures. Below we
will focus on the 26 metabolites listed in the expression signature adjusted for all
clinical variables. We found, in concordance with previous findings in both CSF
and plasma, that AD is associated with decreased levels of amino acids and lipids
[11, 34].
Sixteen lipids, of whom fourteen triglycerides, were underexpressed, while only
one lipid – SM(d18:1/20:1) – was overexpressed in AD. This is in agreement with
a large and recent lipidomics study that reported a decrease of most plasma lipids
in AD and in particular an association of long-chain triglycerides with AD [34].
Moreover, supplementation of medium-chain triglycerides has been tested in AD
to correct neuronal hypometabolism and might show some benefit for APOE 4
negative AD patients [35].
Multiple amino acids were also decreased in AD, amongst which 2-AAA acid
(an intermediate of the lysine-pathway) and Tyrosine. Plasma disturbances of the
lysine-pathway have been suggested to differentiate controls from MCI and AD pa-
tients [11]. Decreased Tyrosine (a precursor for the neurotransmitters dopamine
and norepinephrine) levels were also reported in an earlier study comparing metabo-
lite levels in serum samples of AD patients and healthy controls [36]. More-
over, vanylmandellic acid – an end-product of the Tyrosine-pathway – was found
to be elevated in the CSF of AD patients [37], suggesting disturbances of the
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Tyrosine-pathway. Dopamine has been associated with cognitive control [38] and
oral supplementation of Tyrosine has been shown to improve working memory and
information-processing during demanding situations in healthy human adults [39].
Experimental studies are needed to establish if the alterations in peripheral Tyro-
sine metabolism we found in our study, also affect the function of dopamine and
Tyrosine in the central nervous system of AD patients.
4.2. Classification Signature. The metabolites have added value in demarcat-
ing AD cases from controls. This is reflected by the significant improvement of
predictive performance when adding a selection of metabolites to the clinical char-
acteristics and APOE status. Metabolite panels to monitor disease are of great
interest for the clinic. Especially when easy-to-obtain as with blood samples. We
here hint that a metabolite panel could be of added value to the yet available clin-
ical variables and therefore might hold promise for use in, for example, clinical
effect-monitoring.
Oxidative stress has been widely established to play a role in the pathogenesis
of AD [2]. Defining the right markers to measure oxidative stress in vivo is however
still an ongoing process, especially for peripheral markers in AD. We found three
markers of oxidative stress to have strong predictive power in demarcating AD
patients from controls: the isoprostane-pathway derivatives [40] 8,12-iPF-2a IV
and PGD2, and the nitro fatty acid NO2-aLA (C18:3). This result highlights again
that oxidative stress is of strong influence in AD [2, 41].
4.3. Regulatory Signature. The network models revealed another oxidative
stress marker, lysophosphatic acid (LPA C 18:2), to be one of the central play-
ers in both the AD and control networks. It was prominently differentially related
to other metabolites in AD versus control networks, perhaps representing a central
player of metabolic change. Previously, oxidized lipoproteins have been identified
as a possible oxidative stressor in the brain leading to neuronal cell death in AD
[42]. LPA is the most bioactive fraction of oxidized low density lipoprotein [43]. It
has an important signal function and has been linked to the pathogenesis of AD
as in vitro results suggest they support tau phosphorylation and raise levels of β-
secretase, leading to increased Aβ production [43, 44, 45]. Moreover, LPA’s have
been identified as important factors in vascular development, atherosclerosis and
atherotrombogenesis [46, 47, 48]. As LPAs are a modulating factor in both AD and
vascular changes it could be of special interest to further study the role of vascular
factors in AD.
Network models for APOE 4 positive AD subjects were more cohesive and
less random in comparison to APOE 4 negative AD subjects. This suggests the
possibility of structured, APOE 4-driven changes in metabolism. The lack of
cohesiveness for the APOE 4 negative AD group may be natural as this group is
likely heterogeneous in disease etiology. Hence, profiling metabolic subtypes is of
interest for personalized clinical research.
4.4. Strengths and Limitations. One strength of our study is that we used
CSF biomarkers (Aβ and tau) to support the clinical diagnosis of AD and controls.
This makes the metabolic alterations we describe more likely to be AD-specific.
Moreover, with the semi-targeted MS techniques here we were able to integrate
data of four different compound classes and to replicate many findings from other
recent metabolite studies in AD.
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We note that the different signatures are not completely concordant. This is ex-
plained by the different properties studied in each signature. A differential expres-
sion signature explores, for individual metabolites, shifts in distribution. A classifi-
cation signature explores which conjunction of metabolites achieves an appreciable
predictive performance. A regulatory signature, then, assesses which metabolites
are central in the complex network of metabolite interactions. We pose the exam-
ination of multiple signatures as a strength as it uncovers metabolites of interest
at the expression, prediction, and regulatory levels. Assessing only the differential
expression signature, for example, would imply that many metabolites of interest
would go unnoticed.
Among the potential limitations of the study is the relatively small sample size
(n = 248) in comparison to the large number of metabolites studied (p = 230).
However, we used novel statistical methods designed to account for high numbers
of variables with limited case numbers. Moreover, we used non-fasting plasma
samples, while nutritional intake and medications are known to influence metabolite
levels [6, 49]. However, we corrected our results for multiple medication classes.
4.5. Future Directions. Peripheral changes in metabolism in AD are of interest
because it could highlight factors that are influential in the disease-process on a
systemic level. The regulatory signature might be of added value to explore meta-
bolic dysregulation. However, these results are explorative and further work should
focus on providing (dis)confirmation of hypotheses regarding (the effect of) net-
work changes. Experimental studies are needed to establish if the found alterations
in peripheral metabolism are related to the function of metabolites in the central
nervous system of AD patients. In addition, effort should be directed to disen-
tangle if these metabolic alterations are associated with AD-related risk factors
and secondary changes (e.g., malnutrition, ageing, diabetes) or with AD pathology.
Moreover, integrating genomics and metabolomics could be of interest, as well as
an in-depth study of the effect of patient-related and pre-analytical variation on
the metabolome. When its dynamics in terms of patient and pre-analytical influ-
ences are fully understood, it can be a powerful tool for monitoring ongoing biology.
Metabolites as identified in this study, such as for example Tyrosine and 2-AAA,
could then serve as biological effect-monitoring tools in clinical trials.
5. Conclusion
We show that peripheral metabolism is altered in AD patients compared to
controls and between carriers and non-carriers of the APOE 4 allele. Moreover
we show the added value of not only studying metabolic expression signatures,
but to paint the full picture of metabolic change by also exploring classification
and regulatory signatures. These additional signatures can highlight possible pre-
diction and regulatory markers that may be overlooked when studying expression
signatures alone. The consistent element over all signatures are the changes in
the metabolism of amino acids and markers of oxidative stress. In particular, the
amino acid Tyrosine and the oxidative stress compound Lyso-phosphatidic acid
C18:2 were identified as possible key players of metabolic change. This is in con-
cordance with previous literature describing disturbances of the tyrosine pathway
in AD and oxidized lipoproteins as oxidative stressors in the AD brain [36, 37, 42].
Further research is needed to validate these results and to further specify their role
in AD-specific metabolic alteration.
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Research in Context
1. Systematic Review: Molecular aberrations tend to be amplified along
the omics cascade. Hence, there is increasing interest in finding biomarkers for
Alzheimer’s disease (AD) in peripheral fluids such as plasma. Current study adds to
a small body of literature on potential metabolite markers stemming from plasma.
2. Interpretation: Our data are used in a systematic effort to find differential
expression, classification, and network deregulation signatures that demarcate AD
from control cases. These signatures point to certain amines and oxidative stress
markers as drivers behind AD-related metabolic deregulation.
3. Future directions: The results hold promise for the development of a
biomarker panel. Further studies are warranted for replication and panel devel-
opment.
Highlights
(1) Multiple metabolic signatures point to peripheral AD markers for future
validation.
(2) AD may be described by changes in the metabolism of amines and oxidative
stressors.
(3) APOE 4-driven AD and non-APOE 4-driven AD represent different bio-
chemical pathways.
(4) Network analyses of metabolomics data enable the study of metabolic
changes in AD.
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SUPPLEMENTARY TEXT 1
Metabolite Analysis Methods
This supplementary text contains additional information on the metabolite pro-
filing. Section 1 contains general information. Section 2 details on the profiling
methods. Finally, Section 3 contains an overview of the metabolites considered
detected.
1. General Information
Samples were stored at −80◦C until used for further analysis. All samples were
randomized and run in 5 batches which included a calibration line, quality control
(QC) samples and blanks. QC samples were analyzed every 10 samples (or every
15 samples in the oxidative stress platform). The acquired data were evaluated
using MassHunter software (Agilent) and LabSolutions software (Shimadzu). An
in-house written tool was applied that uses the QC samples to compensate for
shifts in the sensitivity of the mass spectrometer throughout the batches [S1.1].
Both internal standard correction and QC correction were applied to the data set
before reporting results. All metabolites comply with the acceptance criteria of
relative standard deviation QC (RSDQC) < 30%.
2. Profiling
2.1. Biogenic Amine Profiling. The amine platform covers amino acids and
biogenic amines employing an AccQ-tag derivatization strategy adapted from the
protocol supplied by Waters. Five µL of each sample was spiked with an internal
standard solution. Then proteins were precipitated by the addition of methanol.
The supernatant was transferred to a new Eppendorf tube and taken to dryness
in a vacuum centrifuge (speedvac). The residue was reconstituted in borate buffer
(pH 8.5) with 6-aminoquinolyl-N -hydrosysuccinimidyl carbamate (AQC) reagent.
After reaction, the vials were transferred to an autosampler tray and cooled to 10◦C
until the injection. One µL of the reaction mixture was injected into the ultra-
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
system.
An Agilent 1290 Infinity ultra-high performance liquid chromatography (UH-
PLC) system with autosampler (Agilent, The Netherlands) was coupled online with
a 6490 Triple quadrupole mass spectrometer (Agilent) operated using MassHunter
data acquisition software (B.04.01; Agilent). The samples were analyzed by UPLC-
MS/MS using an Accq-Tag Ultra column (Waters). The Triple quadrupole MS was
used in the positive-ion electrospray mode and all analytes were monitored in dy-
namic Multiple Reaction Monitoring (dMRM) using nominal mass resolution [S1.2].
2.2. Organic Acid Profiling. This profiling platform, performed with gas
chromatography-MS (GC-MS) technology, covered organic acids. Sample prepa-
ration proceeded by first doing protein precipitation of 50 µL of sample with
2 F.A. DE LEEUW AND C.F.W. PEETERS ET AL.
a crash solvent (MeOH/H2O) with in situ thermal desorption (ISTD) added.
After centrifugation and transferring the supernatant, the solvent was evapo-
rated to complete dryness on the vacuum centrifuge (speedvac). Then, two-
step derivatisation procedures with oximation using methoxyamine hydrochloride
(MeOX, 15 mg/mL in pyridine) as first reaction and silylation using N-Methyl-
N-(trimethylsilyl)trifluoroacetamide (MSTFA) as second reaction were carried out.
After this final step the samples were transferred to the auto sampler vials and 1
µL was injected on GC-MS [S1.3].
The metabolites were measured by gas chromatography on an Agilent Technolo-
gies 7890A equipped with an Agilent Technologies mass selective detector (MSD
5975C) and MultiPurpose Sampler (MPS, MXY016-02A, GERSTEL). Chromato-
graphic separations were performed on a HP-5MS UI (5% Phenyl Methyl Silox),
30m×0.25m ID column with a film thickness of 25m, using helium as the carrier gas
at a flow rate of 1.7 mL/min. A single-quadrupole mass spectrometer with electron
impact ionization (EI, 70 eV) was used. The mass spectrometer was operated in
SCAN mode mass range 50-500.
2.3. Lipid Profiling. The lipid platform covers Cholesteryl ester, Ceremides,
Diacylglycerols, Lysophosphatidylcholines, Lysophosphatidylethanolamine,
Phosphatidylcholines, Phosphatidylethanolamines, Plasmalogen Lysophos-
phatidylcholines, Plasmalogen Phosphatidylcholines, Plasmalogen Phos-
phatidylethanolamines, Sphingomyelins, and Triglycerides. Lipids were extracted
with isopropyl alcohol (IPA). In short, 1000 µL IPA containing calibrant and inter-
nal standards both at C4 levels were added to 10 µL serum to precipitate proteins.
After centrifugation (12, 100 rpm, 10 min, at RT), supernatant containing the
lipids was transferred to vials for Liquid chromatography-MS (LC-MS) analysis.
In total 2.5 µL was injected for analysis.
Chromatographic separation was achieved on an ACQUITY UPLC HSS T3 col-
umn (1.8 µm, 2.1 × 100mm) with a flow of 0.4 mL/min over a 16 min gradient.
The lipid analysis is performed on a UPLC-ESI-Q-TOF (Agilent 6530, Jose, CA,
USA) high resolution mass spectrometer using reference mass correction. Lipids
were detected in full scan in the positive ion mode [S1.4].
2.4. Oxidative Stress Profiling. The oxidative stress platform covers iso-
prostanes, prostaglandins, nitro-fatty acids, lyso-sphingolipids, lysophosphatidic
acids, alkyl-lysophosphatidic acids and cyclic-phosphatidic acids. One hundred and
fifty µL of each sample was spiked with an internal standard solution. The metabo-
lite extraction is performed via liquid-liquid extraction. To extract the compounds
from the aqueous phase, butanol and ethylacetate are used. After collection, the
organic phase is concentrated by first drying and then reconstitution in a smaller
volume. After reconstitution, the extract is divided in two vials (one for each chro-
matography) and used for injection on UPLC-MS/MS. The oxidative stress plat-
form is divided in two chromatographic methods: low and high pH. In the low pH
method, isoprostanes, prostaglandins, nitro-fatty acids and lyso-sphingolipids are
analyzed. The high pH method covers lyso-sphingolipids, lysophosphatidic acids,
alkyl-lysophosphatidic acids and cyclic-phosphatidic acids.
A Shimadzu system with three high pressure pumps (LC-30AD), a controller
(CBM-20Alite), an autosampler (SIL-30AC) and an oven (CTO-30A) from Shi-
madzu Benelux, was coupled online with a LCMS-8050 Triple quadrupole mass
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spectrometer (Shimadzu) operated using LabSolutions data acquisition software
(Version 5.72, Shimadzu). The samples were analyzed by UPLC-MS/MS using a
Kromasil Eternity XT C18 column (Akzo Nobel) for high pH and an Acquity BEH
C18 column (Waters) for the low pH method. The Triple quadrupole MS was used
in polarity switching mode and all analytes were monitored in dynamic Multiple
Reaction Monitoring (dMRM).
3. Detected Compounds
After QC correction, 53 amine compounds, 22 organic acid compounds, 120
lipid compounds, and 40 oxidative stress compounds are detected, respectively.
The detected compounds are listed in the tables below. These tables make use
of the following abbreviations: HMDB = Human Metabolome Database; ID =
identifier; InChI = International Union of Pure and Applied Chemistry (IUPAC)
International Chemical Identifier; Lipid Maps = LIPID Metabolites and Pathways
Strategy [S1.5]. Detected amine, organic acid, lipid, and oxidative stress compounds
are listed in Tables S1.1, S1.2, S1.3, and S1.4, respectively.
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Table S1.1. Detected amine compounds.
Metabolite Chemical formula HMDB ID InChI Key
1-Methylhistidine C7H11N3O2 HMDB00001 BRMWTNUJHUMWMS-LURJTMIESA-N
2-Aminoadipic acid C6H11NO4 HMDB00510 OYIFNHCXNCRBQI-UHFFFAOYSA-N
3-Aminoisobutyric acid C4H9NO2 HMDB00452 QWCKQJZIFLGMSD-VKHMYHEASA-N
3-Methoxytyramine C9H13NO2 HMDB00022 DIVQKHQLANKJQO-UHFFFAOYSA-N
3-Methoxytyrosine C10H13NO4 HMDB01434 PFDUUKDQEHURQC-UHFFFAOYSA-N
3-Methylhistidine C7H11N3O2 HMDB00479 JDHILDINMRGULE-LURJTMIESA-N
4-Hydroxyproline C5H9NO3 HMDB00725 PMMYEEVYMWASQN-DMTCNVIQSA-N
5-Hydroxylysine C6H14N2O3 HMDB00450 YSMODUONRAFBET-UHNVWZDZSA-N
ADMA C8H18N4O2 HMDB01539 YDGMGEXADBMOMJ-LURJTMIESA-N
Alanine C3H7NO2 HMDB00161 QNAYBMKLOCPYGJ-REOHCLBHSA-N
Alpha-aminobutyric acid C4H9NO2 HMDB03911 QCHPKSFMDHPSNR-UHFFFAOYSA-N
Arginine C6H14N4O2 HMDB00517 ODKSFYDXXFIFQN-BYPYZUCNSA-N
Asparagine C4H8N2O3 HMDB00168 DCXYFEDJOCDNAF-REOHCLBHSA-N
Aspartic acid C4H7NO4 HMDB00191 CKLJMWTZIZZHCS-REOHCLBHSA-N
Carnosine C9H14N4O3 HMDB00033 CQOVPNPJLQNMDC-ZETCQYMHSA-N
Citrulline C6H13N3O3 HMDB00904 RHGKLRLOHDJJDR-BYPYZUCNSA-N
Cysteine C3H7NO2S HMDB00574 XUJNEKJLAYXESH-REOHCLBHSA-N
Dopamine C8H11NO2 HMDB00073 VYFYYTLLBUKUHU-UHFFFAOYSA-N
Ethanolamine C2H7NO HMDB00149 HZAXFHJVJLSVMW-UHFFFAOYSA-N
Gamma-aminobutyric acid C4H9NO2 HMDB00112 BTCSSZJGUNDROE-UHFFFAOYSA-N
Gamma-glutamylalanine C8H14N2O5 HMDB06248 WQXXXVRAFAKQJM-WHFBIAKZSA-N
Glutamic acid C5H9NO4 HMDB00148 WHUUTDBJXJRKMK-VKHMYHEASA-N
Glutamine C5H10N2O3 HMDB00641 ZDXPYRJPNDTMRX-VKHMYHEASA-N
Glutathione C10H17N3O6S HMDB00125 RWSXRVCMGQZWBV-WDSKDSINSA-N
Glycine C2H5NO2 HMDB00123 DHMQDGOQFOQNFH-UHFFFAOYSA-N
Glycylglycine C4H8N2O3 HMDB11733 YMAWOPBAYDPSLA-UHFFFAOYSA-N
Histamine C5H9N3 HMDB00870 NTYJJOPFIAHURM-UHFFFAOYSA-N
Histidine C6H9N3O2 HMDB00177 HNDVDQJCIGZPNO-YFKPBYRVSA-N
Homoserine C4H9NO3 HMDB00719 UKAUYVFTDYCKQA-VKHMYHEASA-N
Isoleucine C6H13NO2 HMDB00172 AGPKZVBTJJNPAG-WHFBIAKZSA-N
Kynurenine C10H12N2O3 HMDB00684 YGPSJZOEDVAXAB-QMMMGPOBSA-N
Leucine C6H13NO2 HMDB00687 ROHFNLRQFUQHCH-YFKPBYRVSA-N
Lysine C6H14N2O2 HMDB00182 KDXKERNSBIXSRK-YFKPBYRVSA-N
Methionine C5H11NO2S HMDB00696 FFEARJCKVFRZRR-BYPYZUCNSA-N
Methionine sulfoxide C5H11NO3S HMDB02005 QEFRNWWLZKMPFJ-UHFFFAOYSA-N
Methyldopa C10H13NO4 HMDB11754 CJCSPKMFHVPWAR-JTQLQIEISA-N
N6,N6,N6-Trimethyllysine C9H20N2O2 HMDB01325 MXNRLFUSFKVQSK-QMMMGPOBSA-N
O-Acetylserine C5H9NO4 HMDB03011 VZXPDPZARILFQX-BYPYZUCNSA-N
O-Phosphoethanolamine C2H8NO4P HMDB00224 SUHOOTKUPISOBE-UHFFFAOYSA-N
Ornithine C5H12N2O2 HMDB00214 AHLPHDHHMVZTML-BYPYZUCNSA-N
Phenylalanine C9H11NO2 HMDB00159 COLNVLDHVKWLRT-QMMMGPOBSA-N
Pipecolic acid C6H11NO2 HMDB00716 HXEACLLIILLPRG-YFKPBYRVSA-N
Proline C5H9NO2 HMDB00162 ONIBWKKTOPOVIA-BYPYZUCNSA-N
Putrescine C4H12N2 HMDB01414 KIDHWZJUCRJVML-UHFFFAOYSA-N
Sarcosine C3H7NO2 HMDB00271 FSYKKLYZXJSNPZ-UHFFFAOYSA-N
SDMA C8H18N4O2 HMDB03334 HVPFXCBJHIIJGS-LURJTMIESA-N
Serine C3H7NO3 HMDB00187 MTCFGRXMJLQNBG-REOHCLBHSA-N
Serotonin C10H12N2O HMDB00259 QZAYGJVTTNCVMB-UHFFFAOYSA-N
Taurine C2H7NO3S HMDB00251 XOAAWQZATWQOTB-UHFFFAOYSA-N
Threonine C4H9NO3 HMDB00167 AYFVYJQAPQTCCC-GBXIJSLDSA-N
Tryptophan C11H12N2O2 HMDB00929 QIVBCDIJIAJPQS-VIFPVBQESA-N
Tyrosine C9H11NO3 HMDB00158 OUYCCCASQSFEME-QMMMGPOBSA-N
Valine C5H11NO2 HMDB00883 KZSNJWFQEVHDMF-BYPYZUCNSA-N
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Table S1.2. Detected organic acid compounds.
Metabolite Identifier
2-hydroxybutyric acid HMDB00008
Citric acid HMDB00094
Glutamic acid HMDB00148
Glycolic acid HMDB00115
L-Lactic acid HMDB00190
Malic acid HMDB00744
2-Ketoglutaric acid HMDB00208
Succinic acid HMDB00254
Fumaric acid HMDB00134
Pyruvic acid HMDB00243
Methylmalonic acid HMDB00202
Pyroglutamic acid HMDB00267
Isocitrate HMDB00193
3-hydroxybutyric acid HMDB00357
3-Phosphoglyceric acid HMDB00807
Aspartic acid HMDB00191
Iminodiacetate HMDB11753
S-3-Hydroxyisobutyric acid HMDB00023
3-Hydroxyisovaleric acid HMDB00754
Glyceric acid HMDB00139
Uracil HMDB00300
Cis-Aconitic acid HMDB00072
Table S1.3. Detected lipid compounds.
Lipid class Lipidmaps Metabolite species
Cholesteryl ester (CE) ST0102 CE(18:1); CE(18:2)
Ceremides (Cer) SP02 Cer(d18:1/24:0)
Diacylglycerol (DG) GL0201 DG(36:2); DG(36:3)
Lysophosphatidylcholine (LPC) GP0105 LPC(14:0); LPC(16:0); LPC(16:1); LPC(18:0);
LPC(18:1); LPC(18:2); LPC(18:3); LPC(20:3);
LPC(20:4); LPC(20:5); LPC(22:6)
Lysophosphatidylethanolamine GP0205 LPE(18:0)
(LPE)
Phosphatidylcholine (PC) GP0101 PC(32:0); PC(32:1); PC(32:2); PC(34:1); PC(34:2);
PC(34:3); PC(34:4); PC(36:1); PC(36:2); PC(36:3);
PC(36:4); PC(36:5); PC(36:6); PC(38:2); PC(38:3);
PC(38:5); PC(38:6); PC(40:4); PC(40:5); PC(40:7)
Phosphatidylethanolamine (PE) GP0201 PE(38:2); PE(38:4)
Plasmalogen GP0106 LPC(O-16:0); LPC(O-16:1); LPC(O-18:1)
Lysophosphatidylcholine (pLPC)
Plasmalogen GP0102 PC(O-34:1); PC(O-34:2); PC(O-34:3); PC(O-36:4);
Phosphatidylcholine (pPC) PC(O-36:5); PC(O-36:6); PC(O-38:4); PC(O-38:5);
PC(O-38:6); PC(O-44:5)
Plasmalogen GP0202 PE(O-36:5); PE(O-38:5); PE(O-38:7)
Phosphatidylethanolamine (pPE)
Sphingomyelins (SM) SP0301 SM(d18:1/14:0); SM(d18:1/15:0); SM(d18:1/16:0);
SM(d18:1/16:1); SM(d18:1/18:0); SM(d18:1/18:1);
SM(d18:1/18:2); SM(d18:1/20:0); SM(d18:1/20:1);
SM(d18:1/21:0); SM(d18:1/22:0); SM(d18:1/22:1);
SM(d18:1/23:0); SM(d18:1/23:1); SM(d18:1/24:0);
SM(d18:1/24:1); SM(d18:1/24:2); SM(d18:1/25:0)
Triglycerides (TG) GL0301 TG(42:0); TG(44:0); TG(44:1); TG(46:0); TG(46:1);
TG(46:2); TG(48:0); TG(48:1); TG(48:2); TG(48:3);
TG(50:0); TG(50:1); TG(50:2); TG(50:3); TG(50:4);
TG(51:1); TG(51:2); TG(51:3); TG(52:0); TG(52:1);
TG(52:2); TG(52:3); TG(52:4); TG(52:5); TG(54:0);
TG(54:1); TG(54:2); TG(54:3); TG(54:4); TG(54:5);
TG(54:6); TG(56:0); TG(56:1); TG(56:2); TG(56:3);
TG(56:6); TG(56:7); TG(56:8); TG(57:2); TG(58:1);
TG(58:10); TG(58:2); TG(58:3); TG(58:8); TG(58:9);
TG(60:2); TG(O-50:0)
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Table S1.4. Detected oxidative stress compounds.
Compound name Compound class Lipid Maps ID
2,3-dinor-8-iso-PGF2a Isoprostane LMFA03110010
5-iPF2a VI Isoprostane LMFA03110010
8-iso-PGF2a (15-F2t-IsoP) Isoprostane LMFA03110001
8,12-iPF2a IV Isoprostane -
aLPA C16:1 Alkyl-lyso-phosphatidic acid -
aLPA C18:1 Alkyl-lyso-phosphatidic acid -
cLPA C16:0 Cyclic-lyso-phosphatidic acid LMGP00000057
cLPA C18:0 Cyclic-lyso-phosphatidic acid LMGP00000055
cLPA C18:1 Cyclic-lyso-phosphatidic acid LMGP00000056
cLPA C18:1 Cyclic-lyso-phosphatidic acid -
cLPA C18:2 Cyclic-lyso-phosphatidic acid -
cLPA C20:3 Cyclic-lyso-phosphatidic acid -
cLPA C20:4 Cyclic-lyso-phosphatidic acid -
iPF2a-Unknown - -
LPA C14:0 Lyso-phosphatidic acid LMGP10050007
LPA C16 Lyso-phosphatidic acid LMGP10050006
LPA C16:1 Lyso-phosphatidic acid LMGP10050016
LPA C18 Lyso-phosphatidic acid LMGP10050005
LPA C18:1 Lyso-phosphatidic acid LMGP10050008
LPA C18:2 Lyso-phosphatidic acid LMGP10050017
LPA C18:3 Lyso-phosphatidic acid LMGP10050023
LPA C20:1 Lyso-phosphatidic acid LMGP10050026
LPA C20:3 Lyso-phosphatidic acid LMGP10050028
LPA C20:4 Lyso-phosphatidic acid LMGP10050013
LPA C20:5 Lyso-phosphatidic acid LMGP10050033
LPA C22:4 Lyso-phosphatidic acid LMGP10050020
LPA C22:5 Lyso-phosphatidic acid -
LPA C22:6 Lyso-phosphatidic acid LMGP10050019
NO2-aLA (C18:3) Nitro-Fatty acid -
NO2-LA (C18:2) Nitro-Fatty acid LMFA01120001/2
NO2-OA (C18:1) Nitro-Fatty acid LMFA01120003/4
PAF C16:0 Platelet activating factor LMGP01020046
PGA2 Prostaglandins LMFA03010035
PGD2 Prostaglandins LMFA03010004
PGE2 Prostaglandins LMFA03010003
PGF2a Prostaglandins LMFA03010002
S1P C18:1 Lyso-sphingolipid LMSP01050001
SPH C18:1 Lyso-sphingolipid LMSP01010001
SPHA C18:0 Lyso-sphingolipid LMSP01020001
SPHA-1-P C18:0 Lyso-sphingolipid LMSP01050002
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SUPPLEMENTARY TEXT 2
Statistical Analyzes: Approaches and Results
This supplementary text contains additional information on the data analysis.
Section 1 contains information on processing the metabolite data for statistical
analyzes. Section 2 then contains extensive information on the analyzes surrounding
the differential expression, classification, and regulatory signatures. This section
also contains all obtained results. Please note that, as this supplementary text is
self-contained, there is some redundancy in presentation.
1. Data and Data Processing
1.1. Data. Plasma samples of 150 subjects with Alzheimer’s disease (AD) and
150 subjects with subjective cognitive decline (SCD) were available. Subjects with
SCD were used as cognitively normal controls in this study. Of these 300 subjects
263 (136 AD and 127 SCD) had their diagnosis confirmed by cerebral spinal fluid
(CSF) markers (t-tau/Aβ42 > 0.52 for AD diagnosis). The 263 subjects with
CSF-confirmed diagnosis were used for further study. Metabolite concentrations
in four metabolite classes were determined using four different mass spectrometry
platforms: amines (53), organic acids (22), lipids (120) and oxidative stress (40)
compounds (see Supplementary Text 1 ).
1.2. Data Processing. Metabolites with more than 10% missing observations
were removed, leading to the removal of 5 metabolites (the oxidative stress com-
pound iPF2a-Unknown, and the lipids CE(18:1), TG(57:2), TG(58:3), and PE(O-
38:7)). Three data samples (i.e., vectors of observed metabolite abundancies stem-
ming from corresponding plasma samples) were removed as their (plasma) quality
was deemed unsure. These samples had many (30 or more) concentrations below
the limit of detection (LOD) that could not be attributed to instrumental errors.
Twelve additional data samples were removed due to instrumental errors in one
or more platforms. Hence, we only retain data samples that were free of instru-
mental errors across all four different mass spectrometry platforms. The remaining
missing values are attributable to concentrations failing the LOD. These (feature-
specific) missing values were imputed by half of the lowest observed value (for the
corresponding feature). The final metabolic data set thus contained n = 248 data
samples (127 AD and 121 SCD) and p = 230 metabolic features.
In addition to metabolomics data, phenotypic data (clinical and demographic
characteristics such as height, weight, and APOE 4 allele status) were evaluated
for their possible confounding effects in the expression and classification signatures
demarcating the AD and SCD groups. The missing observations on these vari-
ables (14 at most, for the height variable) were imputed. Continuous variables
were imputed on the basis of Bayesian linear regression, polytomous variables were
imputed on the basis of polytomous regression, and binary variables were imputed
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Table S2.1. List of clinical variables.
Variable Measurement
Anthropometric:
Age years at diagnosis
Sex male or female
APOE 4 allele status at least one 4 allele: yes, no
Mean arterial pressure approximated by DBP + 1
3
(SBP−DBP)
Body mass index weightkg/height
2
m
Intoxications:
Smoking status: current, former, never
Alcohol current consumption of: yes, no
Comorbidities:
Hypertension present: yes, no
Diabetes Mellitus present: yes, no
Hypercholesterolemia present: yes, no
Medication:
Cholesterol lowering medications usage: yes, no
Antidepressant medications usage: yes, no
Antiplatelet medications usage: yes, no
on the basis of logistic regression [S2.1]. To relief ‘correctional stress’ on the ex-
pression and classification signatures, certain aggregational clinical measures were
calculated. The Body Mass Index (BMI) was calculated as weightkg/height
2
m. In
addition, the Mean Arterial Pressure (MAP) was approximated from the systolic
blood pressure (SBP) and diastolic blood pressure (DBP) by DBP+ 13 (SBP−DBP).
See Table S2.1 for a full list of considered confounders.
2. Signatures
2.1. Differential Expression Signature.
2.1.1. Approach. Differential metabolic expression between AD and SCD subjects
was assessed by using nested linear models. We tested, for each individual metabo-
lite, if its addition to a model containing the clinical characteristics (see Table S2.1)
significantly contributed to model fit. One then assesses if, conditional on the ef-
fects of the clinical characteristics, metabolic expression does indeed differ between
the AD and SCD groups. Let BGk represent the kth background or clinical variable
and let IAD denote an indicator variable for AD group-membership. We are then
interested in testing the following (abusing notation somewhat) nested models
metabolitej = β0 +
m∑
k=1
βkBGk + (S2.1)
metabolitej = β0 +
m∑
k=1
βkBGk + β(m+1)IAD + ,(S2.2)
where the reduced model in (S2.1) is clearly nested in the full model (S2.2). This
entails a test for nested models which, in this case, is equivalent to testing H0 :
β(m+1) = 0 versus Ha : β(m+1) 6= 0. The associated test statistic F (see any
standard statistics textbook) is distributed as F1,n−(m+2) under the null hypothesis.
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Table S2.2. Differentially expressed metabolites.
Metabolite Compound class p-value Adjusted p-value
2-Aminoadipic acid Amines .0003110134 .03071051
TG(51:3) Lipids: Triglycerides .0005518318 .03071051
3-Hydroxyisovaleric acid Organic acids .0005645572 .03071051
Tyrosine Amines .0006614924 .03071051
TG(54:6) Lipids: Triglycerides .0009136006 .03071051
TG(50:4) Lipids: Triglycerides .0010320542 .03071051
S-3-Hydroxyisobutyric acid Organic acids .0011085893 .03071051
TG(56:8) Lipids: Triglycerides .0012115039 .03071051
Methyldopa Amines .0012272994 .03071051
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane .0013352397 .03071051
TG(48:3) Lipids: Triglycerides .0017977057 .03703538
O-Acetylserine Amines .0020920976 .03703538
TG(48:2) Lipids: Triglycerides .0025274816 .03703538
Methylmalonic acid Organic acids .0026395625 .03703538
TG(46:2) Lipids: Triglycerides .0027475334 .03703538
Valine Amines .0027973120 .03703538
TG(50:3) Lipids: Triglycerides .0031949553 .03703538
TG(52:4) Lipids: Triglycerides .0034264336 .03703538
TG(52:5) Lipids: Triglycerides .0034406945 .03703538
TG(56:7) Lipids: Triglycerides .0034900406 .03703538
TG(48:0) Lipids: Triglycerides .0035736266 .03703538
Ornithine Amines .0036249029 .03703538
SM(d18:1/23:0) Lipids: Sphingomyelins .0037035385 .03703538
SM(d18:1/20:1) Lipids: Sphingomyelins .0048428315 .04491679
TG(48:1) Lipids: Triglycerides .0049569537 .04491679
TG(58:10) Lipids: Triglycerides .0050775504 .04491679
The p-value for the observed test statistic can be obtained in reference to this
distribution.
We have a multiple testing problem as we need to perform this test for each
individual metabolite. Our approach to multiple testing is by controlling the False
Discovery Rate (FDR), i.e., we aim to control “the expected proportion of falsely
rejected hypotheses” [S2.2]. We control the FDR at .05.
2.1.2. Results. The metabolic features that survive multiple testing correction are
listed in Table S2.2. The differential distributions for these features are depicted
in Figures S2.1, S2.2, and S2.3. We see that all implicated features (except for
SM(d18:1/20:1)) are underexpressed in the AD group relative to the control group.
Table S2.3 contains, for purposes of comparison, the list of metabolic features that
survive multiple testing correction when testing nested models in which only sex and
age are used as possible confounders. We see that under less stringent corrections
the list of potentially differentially expressed metabolites is longer. Substantive
corrections harness against overoptimistic expression signatures.
2.2. Classification Signature.
2.2.1. Approach. Metabolic classification signatures for the prediction of group
membership (AD or SCD) were constructed by way of penalized logistic regres-
sion with a Lasso-penalty [S2.3]. Two penalized settings were considered: (i) the
Lasso selects among the metabolites while the clinical characteristics go unpenal-
ized; and (ii) the Lasso selects among the metabolites without considering the
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Figure S2.1. Violin plots of (a selection of) the metabolites that survive
multiple testing correction. Violin plots [S2.4] combine the familiar box plot
with a kernel density to better represent the distribution of the data. We see
relative underexpression in the AD group for all depicted metabolites. The
associated adjusted p-values can be found in Table S2.2. The remaining violin
plots can be found in Figures S2.2 and S2.3.
clinical characteristics. The resulting models were compared to an unpenalized lo-
gistic regression model that (iii) considered only the clinical characteristics. Model
estimation collides with minimizing the negative log-likelihood of the logistic model
under an `1-penalty. The general problem can then be stated as:
(S2.3) arg min
β0,βu,βp
{
− 1
n
L (β0,βu,βp; y,Xu,Xp) + λ1‖βp‖1
}
,
with L(·) denoting the log-likelihood of the logistic model, y the binary n-
dimensional response vector, Xu denoting the (n × m)-dimensional matrix of
clinical-predictors, Xp denoting the (n × p)-dimensional matrix of metabolite-
predictors, βu an m-dimensional vector of unpenalized regression coefficients, βp
a p-dimensional vector of penalized regression coefficients, and with β0 denoting
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Figure S2.2. Violin plots of (a selection of) the metabolites that survive
multiple testing correction. Violin plots [S2.4] combine the familiar box plot
with a kernel density to better represent the distribution of the data. We see
relative underexpression in the AD group for all depicted metabolites. The
associated adjusted p-values can be found in Table S2.2. The remaining violin
plots can be found in Figures S2.1 and S2.3.
an intercept. Lastly, λ1‖ · ‖1 indicates the `1-norm with penalty parameter λ1,
generally referred to as the Lasso-penalty. The Lasso-penalty enables estimation in
our setting where the feature to observation ratio (230/248) is too high for stan-
dard logistic regression. It also achieves automatic model (i.e., feature) selection.
The problem in S2.3 is generally stated, in the sense that it captures all situa-
tions of interest. In situation (iii) only the clinical predictors Xu are considered,
such that the unpenalized parameters β0 and β
u are estimated. In situation (ii)
only the metabolite-predictors Xp are considered, such that, next to β0, the penal-
ized parameters in βp are estimated. Situation (i) combines the former situations
and, hence, considers the the general problem, estimating both unpenalized and
penalized parameters. The optimal penalty parameter in the penalized models was
determined on the basis of leave-one-out cross-validation (LOOCV) of the model
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Figure S2.3. Violin plots of (a selection of) the metabolites that survive
multiple testing correction. Violin plots [S2.4] combine the familiar box plot
with a kernel density to better represent the distribution of the data. We see
relative underexpression in the AD group for all depicted metabolites except
SM(d18:1/20:1). The associated adjusted p-values can be found in Table S2.2.
The remaining violin plots can be found in Figures S2.1 and S2.2.
likelihood. Predictive performance of all models was assessed by way of (the com-
parison of) Receiver Operating Characteristic (ROC) curves and Area Under the
ROC Curves (AUCs). ROC curves and AUCs for all models were produced by
10-fold cross-validation.
Note that the metabolic features were scaled in the classification exercises. The
(regularized) regression makes use of (in some sense) the covariance matrix of the
features. However, the variability of the features may differ substantially. In such
a situation the features with (relatively) extreme variability may drive the results.
Hence, it is appropriate to perform regularization on the standardized scale.
2.2.2. Results. Model performances can be found in Figure S2.4. The prediction
model carrying the clinical variables only resulted in an AUC of .736. The model
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Table S2.3. Differentially expressed metabolites when correcting
for sex and age only.
Metabolite Compound class p-value Adjusted p-value
2-Aminoadipic acid Amines 1.236871e−07 2.844803e−05
Valine Amines 3.316148e−06 3.494500e−04
Tyrosine Amines 4.558044e−06 3.494500e−04
Methyldopa Amines 7.515081e−06 4.321172e−04
Lysine Amines 2.749770e−05 1.264894e−03
Methylmalonic acid Organic acids 4.222770e−05 1.390688e−03
S-3-Hydroxyisobutyric acid Organic acids 4.232528e−05 1.390688e−03
TG(48:0) Lipids: Triglycerides 7.904916e−05 2.272663e−03
TG(50:4) Lipids: Triglycerides 9.542238e−05 2.438572e−03
TG(48:2) Lipids: Triglycerides 1.144591e−04 2.472172e−03
TG(51:3) Lipids: Triglycerides 1.182343e−04 2.472172e−03
TG(54:6) Lipids: Triglycerides 1.305959e−04 2.503088e−03
TG(50:3) Lipids: Triglycerides 1.629475e−04 2.882490e−03
TG(50:2) Lipids: Triglycerides 1.754559e−04 2.882490e−03
TG(50:1) Lipids: Triglycerides 2.217775e−04 3.400588e−03
TG(48:1) Lipids: Triglycerides 2.421916e−04 3.481504e−03
TG(52:4) Lipids: Triglycerides 3.157891e−04 4.141486e−03
TG(48:3) Lipids: Triglycerides 3.241163e−04 4.141486e−03
Leucine Amines 4.124135e−04 4.871236e−03
LPC(18:1) Lipids: Lysophosphatidylcholine 4.235858e−04 4.871236e−03
TG(46:2) Lipids: Triglycerides 5.465651e−04 5.986189e−03
TG(50:0) Lipids: Triglycerides 6.518719e−04 6.815024e−03
TG(52:5) Lipids: Triglycerides 7.216611e−04 7.216611e−03
TG(52:3) Lipids: Triglycerides 1.149358e−03 1.101469e−02
TG(51:2) Lipids: Triglycerides 1.393980e−03 1.252523e−02
TG(56:8) Lipids: Triglycerides 1.451992e−03 1.252523e−02
Isoleucine Amines 1.470353e−03 1.252523e−02
2-hydroxybutyric acid Organic acids 1.704211e−03 1.399888e−02
3-Hydroxyisovaleric acid Organic acids 1.845997e−03 1.464067e−02
TG(51:1) Lipids: Triglycerides 1.996360e−03 1.530543e−02
SM(d18:1/20:1) Lipids: Sphingomyelins 2.242748e−03 1.663974e−02
TG(52:1) Lipids: Triglycerides 2.377869e−03 1.709093e−02
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane 2.670123e−03 1.860995e−02
Proline Amines 3.197010e−03 2.162683e−02
TG(54:5) Lipids: Triglycerides 3.389655e−03 2.227487e−02
TG(56:7) Lipids: Triglycerides 3.846194e−03 2.401863e−02
PGD2 Lipids: Prostaglandins 3.863867e−03 2.401863e−02
TG(46:1) Lipids: Triglycerides 4.273714e−03 2.586722e−02
PC(O-44:5) Lipids: Plasmalogen Phosphatidylcholine 4.595494e−03 2.683819e−02
LPA C14:0 Lyso-phosphatidic acid 4.667512e−03 2.683819e−02
PC(O-34:1) Lipids: Plasmalogen Phosphatidylcholine 5.876174e−03 3.296390e−02
LPC(20:4) Lipids: Lysophosphatidylcholine 7.163584e−03 3.922915e−02
SM(d18:1/24:2) Lipids: Sphingomyelins 7.371942e−03 3.943132e−02
8,12-iPF2a IV Oxidative stress: Isoprostane 8.208661e−03 4.290891e−02
TG(46:0) Lipids: Triglycerides 8.513935e−03 4.351567e−02
5-iPF2a VI Oxidative stress: Isoprostane 9.211706e−03 4.589083e−02
TG(52:2) Lipids: Triglycerides 9.377692e−03 4.589083e−02
SM(d18:1/16:0) Lipids: Sphingomyelins 9.782507e−03 4.687451e−02
TG(58:10) Lipids: Triglycerides 1.063227e−02 4.861745e−02
Ornithine Amines 1.064486e−02 4.861745e−02
Histidine Amines 1.078039e−02 4.861745e−02
that used the Lasso for selection amongst the metabolites sorts a comparable clas-
sification performance, yielding an AUC of approximately .7. The model that
adds a (Lasso-based) selection of metabolites to the clinical variables then im-
proves predictive performance along the full false positive rate range, sorting a
AUC of .79. Table S2.4 contains the metabolites selected in the selection-amongst-
metabolites-only situation. Table S2.5 then contains the metabolites selected in
the selection-amongst-metabolites-whilst-clinical-variables-present situation. The
highlighted features in these tables are also present in the differential expression
signature (see Section 2.1). We see that the signs of their effects concur with the
pattern of AD-associated under- and overexpression present in the differential ex-
pression signature.
Note that the Lasso selects features from all metabolite classes. To assess if the
metabolite-class has predictive power a group-regularized logistic ridge regression
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[S2.5] was used in which the metabolite-class serves as co-data. This analysis indi-
cated that the metabolite-class forms weakly informative co-data. This strengthens
faith in the Lasso results. The strongest predictor amongst the clinical variables is
(naturally) APOE 4 allele status.
2.3. Regulatory Signature.
2.3.1. Graphical Modeling. A differential expression signature represents the fea-
tures that are relatively under- or overexpressed in diagnostic groups of interest.
This signature does not have to concur with the classification signature completely,
as the latter (i) chooses amongst multicollinear features and (ii) emphasizes predic-
tion rather than shifts in location. The classification signature, in turn, is limited
in its capacity to represent complex dependencies amongst the metabolites (of in-
terest). Hence, we seek to explore a third signature: The regulatory signature.
This signature intends to uncover deregulation in metabolic biochemical pathways
as pertaining to the AD disease process. A metabolic pathway can be thought of
as a collection of metabolic features originating from all over the metabolome, that
work interdependently to regulate some biochemical (disease) process. Hence, a
Figure S2.4. ROC curves for the classification models. The grey line
represents the ROC curve for the unpenalized logistic regression model that
entertains the clinical characteristics only. The red line represents the ROC
curve for the logistic model in which the Lasso performed variable selection
amongst the metabolites (and that does not consider the clinical characteris-
tics). The blue line represents the ROC curve of the logistic model in which
the clinical characteristics are present while the Lasso may select amongst the
metabolites. The clinical variables are listed in Table S2.1. Appears as Figure
2 in the main text.
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Table S2.4. Selected metabolites and parameter estimates when
considering only metabolites as potential predictors.
Metabolite Compound class βˆ
LPC(18:1) Lipids: Lysophosphatidylcholine .431701077
PGD2 Oxidative stress: Prostaglandins −.335722610
8,12-iPF2a IV Oxidative stress: Isoprostane −.321506682
O-Acetylserine Amines −.290694860
Methyldopa Amines −.226545678
NO2-aLA (C18:3) Oxidative stress: Nitro-Fatty acid −.214894781
Methylmalonic acid Organic acids −.211631150
TG(51:3) Lipids: Triglycerides −.202508671
Tyrosine Amines −.192600743
Serine Amines .151993825
LPC(20:4) Lipids: Lysophosphatidylcholine .143911633
Arginine Amines .139364338
SM(d18:1/23:0) Lipids: Sphingomyelins −.138378505
Glyceric acid Organic acids −.107386135
Lysine Amines −.101945440
Glycolic acid Organic acids .096537107
cLPA C18:0 Oxidative stress: Cyclic-lyso-phosphatidic acid −.072919587
SM(d18:1/18:0) Lipids: Sphingomyelins .068838390
LPA C22:4 Oxidative stress: Lyso-phosphatidic acid .065264732
LPA C16 Oxidative stress: Lyso-phosphatidic acid −.064109038
3-Methoxytyramine Amines −.063622716
TG(54:6) Lipids: Triglycerides −.062333261
2,3-dinor-8-iso-PGF2a Oxidative stress: Isoprostane −.059017772
PC(O-34:3) Lipids: Plasmalogen Phosphatidylcholine −.048557268
Cis-Aconitic acid Organic acids −.038573969
3-Hydroxyisovaleric acid Organic acids −.034646727
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid −.033059634
2-Aminoadipic acid Amines −.028720481
PC(O-36:6) Lipids: Plasmalogen Phosphatidylcholine −.025814804
PC(O-38:6) Lipids: Plasmalogen Phosphatidylcholine −.021959733
Putrescine Amines −.017413981
TG(48:0) Lipids: Triglycerides −.016328393
Homoserine Amines −.015906351
TG(O-50:0) Lipids: Triglycerides .014668718
Carnosine Amines .012064246
5-iPF2a VI Oxidative stress: Isoprostane −.003633138
Sarcosine Amines −.001072232
pathway is a network. And a network can be represented by a graph. We thus take
interest in graphical modeling.
Graphical modeling refers to a class of probabilistic models that use graphs to
express conditional (in)dependence relations between random variables. We con-
sider graphs G = (V, E) consisting of a finite set V of vertices and set of edges E .
The vertices of the graph correspond to a collection of random variables with prob-
ability distribution P, i.e., {Y1, . . . , Yp} ∼ P. Edges in E consist of pairs of distinct
vertices such that Yj − Yj′ ∈ E . The basic assumption is: {Y1, . . . , Yp} ∼ Np(0,Σ),
with Σ positive definite. Hence, we focus on Gaussian graphical modeling.
In this Gaussian case, conditional independence between a pair of variables cor-
responds to zero entries in the precision matrix. Indeed, let Σˆ−1 = Ωˆ denote a
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Table S2.5. Selected metabolites and parameter estimates when
considering metabolites as potential predictors on top of the clini-
cal variables.
Metabolite Compound class βˆ
PGD2 Oxidative stress: Prostaglandins −.47539723
O-Acetylserine Amines −.45299269
Methylmalonic acid Organic acids −.39360564
NO2-aLA (C18:3) Oxidative stress: Nitro-Fatty acid −.32516790
TG(51:3) Lipids: Triglycerides −.29844463
SM(d18:1/20:1) Lipids: Sphingomyelins .29404906
3-Hydroxyisovaleric acid Organic acids −.27369915
8,12-iPF2a IV Oxidative stress: Isoprostane −.22711647
PE(38:2) Lipids: Phosphatidylethanolamine −.16302211
Gamma-glutamylalanine Amines .15344618
LPC(18:1) Lipids: Lysophosphatidylcholine .15057771
Methyldopa Amines −.14912088
SM(d18:1/23:0) Lipids: Sphingomyelins −.14714005
Putrescine Amines −.14137904
LPC(20:4) Lipids: Lysophosphatidylcholine .12467937
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane −.12101061
LPA C18:3 Oxidative stress: Lyso-phosphatidic acid −.10140491
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid −.09396454
Uracil Organic acids .09348099
Citrulline Amines −.08529403
Histamine Amines .07351094
Glyceric acid Organic acids −.06673703
TG(56:8) Lipids: Triglycerides −.06152908
TG(58:10) Lipids: Triglycerides −.05699948
2,3-dinor-8-iso-PGF2a Oxidative stress: Isoprostane −.04718506
NO2-OA (C18:1) Oxidative stress: Nitro-Fatty acid −.04178329
Glycolic acid Organic acids .04016606
Carnosine Amines .03960024
Serine Amines .03620446
SM(d18:1/18:0) Lipids: Sphingomyelins .01812763
S-3-Hydroxyisobutyric acid Organic acids −.01042997
generic estimate of the precision matrix and consider its transformation to a par-
tial correlation matrix Pˆ. Then the following relations can be shown to hold for all
pairs {Yj , Yj′} ∈ V with j 6= j′ [see, e.g., S2.6]:
(Pˆ)jj′ = 0⇐⇒ (Ωˆ)jj′ = 0⇐⇒ Yj ⊥⊥ Yj′ |V \ {Yj , Yj′} ⇐⇒ Yj 6− Yj′ ,
where V \ {·} denotes set-minus notation and where 6− indicates the absence of
an edge. In words: A zero partial correlation implies a zero precision matrix en-
try which in turn implies that the corresponding two variables are conditionally
independent (given the remaining variables) which then implies the absence of an
edge between these variables in the corresponding graph. Such a graph can thus
be interpreted as a conditional independence graph.
2.3.2. Approach. Now, model selection efforts in Gaussian graphical models focus
on determining the support of the precision matrix. Problematic is that in situations
with p ≈ n or p > n the sample covariance matrix Σˆ = S is ill-behaved or singular
such that it’s inverse (S−1, which would constitute an estimate of the precision
matrix) is unstable or does not exist. Moreover, the metabolic features of interest
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are highly collinear (within the respective metabolite classes). Hence, we need a
regularized estimate of the precision matrix. In addition, we want to take into
account that our data consist of distinct classes of interest. The first distinction is,
naturally, AD versus SCD.
So, we are after jointly estimating multiple regularized precision matrices from
(aggregated) high-dimensional data consisting of distinct classes. From a network
perspective, molecular pathway-deregulation in the disease state is likely character-
ized by the loss of normal (wanted) molecular interactions and the gain of abnormal
(unwanted) molecular interactions. One would thus expect the network topologies
of our groups of interest to primarily share the same structure, while potentially
differing in a number of (topological) locations of interest. Our regularized network
extraction method takes this explicitly into account. Specifically, we employ a spe-
cial case of targeted fused ridge estimation [S2.7], solving the following estimation
problem:
(S2.4) arg max
{Ωg}∈Sp++
{
L ({Ωg}; {Sg})− λ
2
∑
g
∥∥Ωg−T∥∥2F − λf4 ∑
g1,g2
∥∥Ωg1−Ωg2∥∥2F
}
,
where the Sg indicate group-specific sample covariance matrices, λ denotes a strictly
positive ridge penalty, λf denotes a positive fusion penalty, and T denotes a target
matrix. The penalty parameter λ controls the rate of shrinkage of each precision
Ωg towards the corresponding target T, while λf determines the retainment of
entry-wise similarities between Ωg1 and Ωg2 for all class pairs g1 6= g2. For given
penalties the problem can be solved with an block coordinate ascent procedure
[S2.7], resulting in an estimated precision matrix for each class g. In this case
g = 1, 2.
We solve (S2.4) using the class-specific sample covariance matrices (i.e., the sam-
ple covariance matrices of the class-specific data) as the data entries. For the target
T we choose the (weakly informative) p-dimensional identity matrix Ip. The op-
timal penalty parameters were determined by the LOOCV procedure described in
[S2.7]. The optimal penalty values were found to be λ∗ = 2.742348, and λ∗f =
9.867606e-22. These penalty values emphasize individual regularization over re-
tainment of entry-wise similarities, indicating strong differences in class-specific
precision matrices. The support of the estimated class precision matrices was de-
termined by thresholding. For each class-specific matrix, the 100 strongest edges
(in terms of absolute partial correlations) were retained. As metabolic networks
are very dense, retaining the 100 strongest edges is assumed to give a more clear
picture of the most influential regulatory players. The retained partial correlations
range, in absolute value, from .1670877 to .6412267 over the respective classes. All
analyzes were performed with the rags2ridges package [S2.8] in R [S2.9].
2.3.3. Visualization. The first idea regarding the network structures represented by
our class-specific precision matrices can be obtained by simple visualization. Figure
S2.5 contains the class-specific networks visualized with the Fruchterman-Reingold
(FR) algorithm [S2.10]. These networks contain all metabolic features, even when
they are not connected, resulting in ‘hairball’ networks: Networks that are too
tangled to be effectively visualized. They do, however, convey that the strongest
edges implicate metabolic features from all considered metabolite families.
Figure S2.6 contains the pruned class-specific networks visualized with the FR
algorithm. That is, it retains only the class-specific connected components from
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Figure S2.5. The pruned networks more effectively represent the retained topolo-
gies.
To assess the topology more closely, it is beneficial to arrange the metabolic
features in fixed coordinates over the respective groups of interest. Figure S2.7
contains the semi-pruned class-specific networks. They are semi-pruned as in each
class-specific topology all metabolites are depicted that are present in the union of
connected metabolites over all class-specific topologies. This allows us to visualize
the individual topologies with fixed metabolite-coordinates. The FR-based coordi-
nates for the SCD group serve as the reference coordinates for all topologies. We see
that the union of metabolic features is quite tight, suggesting that the core meta-
bolic features for the SCD and AD groups overlap to a large extent. At first glance
the diseased state indeed seem less locally connected. We now turn to numerical
and graph theoretic assessments to support understanding of the topologies.
2.3.4. Global Characteristics. Here, we will assess some global characteristics of
each class-related graph as given in Figure S2.7. Table S2.6 contains some global
metrics for each topology. Please note that formal definitions of all terms relating to
network science as used throughout this supplement can be found in, e.g., [S2.12].
Transitivity is a shape measure, with higher scores indicating stronger local con-
nectivity. Transitivity for the SCD topology is approximately .24, which is higher
than the transitivity score for the AD topology (≈ .15) and also higher than many
other biological networks [S2.12, p. 200 & Section 8.6]. Hence, the SCD topology is
stronger locally connected. Centrality [S2.13] is another shape measure, indicating
Figure S2.5. Class-specific networks visualized with the Fruchterman-
Reingold algorithm. The left-hand panel contains the network for the SCD
group. The right-hand panel contains the network for the AD group. The
metabolite compounds are colored according to metabolite family: Blue for
amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations.
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Figure S2.6. Class-specific pruned networks visualized with the
Fruchterman-Reingold algorithm. The left-hand panel contains the network
for the SCD group. The right-hand panel contains the network for the AD
group. The metabolite compounds are colored according to metabolite family:
Blue for amines, yellow for lipids, orange for organic acids, and purple for ox-
idative stress. Solid edges represent positive partial correlations while dashed
edges represent negative partial correlations.
the degree in which the topology resembles a maximally centralized graph (i.e., a
star graph). The more centralized a network, the more vulnerable it is, in the sense
that it’s connectedness hinges upon few nodes. The centralization scores indicate
that both the SCD and the AD topology are not very centralized.
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Figure S2.7. Class-specific semi-pruned networks visualized with the Fruchterman-Reingold algorithm. The left-hand panel contains
the network for the SCD group. The right-hand panel contains the network for the AD group. The coordinates of the left-hand topology
serve as the reference coordinates. The metabolite compounds are colored according to metabolite family: Blue for amines, yellow for lipids,
orange for organic acids, and purple for oxidative stress. Solid edges represent positive partial correlations while dashed edges represent
negative partial correlations.
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In addition to shape metrics, there are cohesion metrics. One such cohesion
metric is ‘connectedness’, which, for the topologies of interest, is also given in
Table S2.6. Connectedness refers to the “proportion of pairs of nodes that can
reach each other by a path of any length” [S2.14]. The AD topology has a higher
connectedness score than the SCD topology. This is (in part) due to the fact that the
SCD topology has a large disconnected component (consisting of amine compounds
mostly). Figure S2.7 seems to indicate that the AD topology may be characterized
by an increased connection density within amine compounds and between amine
and oxidative stress compounds. This is reflected in the degree density and the
relative outdegree [S2.15] for the respective topologies. The between-metabolite-
family and within-metabolite-family degree densities (Figure S2.8) suggest that the
AD topology is characterized by increased amine-connections (connections in which
at least 1 amine compound is present). The relative outdegrees (Figure S2.9) imply
that the AD topology is characterized by more connections between amines and
organic acid compounds and more connections between amines and oxidative stress
compounds.
Table S2.6. Global metrics for the two topologies of interest (see
Figure S2.7).
Topology Transitivity Connectedness Centralization
SCD group .2424242 .4864865 .0879304
AD .1458967 .6187387 .0879304
Figure S2.8. Heatmaps of degree densities for the SCD and AD networks.
The reported numbers represent the degree density for the (combinations
of) metabolite groups. Degree density represents the number of connections
(edges) divided by the number of possible connections. For example, in the
network for the SCD group the proportion of actual edges relative to the num-
ber of possible edges between Amines and oxidative stress compounds is .0196.
Note that all heatmaps received the same color key. Hence, the color intensities
(i.e., the color-spectrum representations of the cell-numbers) are comparable
over the respective heatmaps.
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Figure S2.9. Heatmaps of relative outdegrees for the class-specific net-
works. The reported numbers represent the relative outdegree for the (combi-
nations of) metabolite groups. The relative outdegree represents the number
of connections (edges) between two metabolite groups divided by the number
of ‘outgoing’ connections for one of these groups. For example, in the network
for the SCD group the number of edges between lipid and oxidative stress
compounds accounts for approximately 29% of all edges involving lipids and
approximately 49% of all edges involving oxidative stress compounds. Note
that all heatmaps received the same color key. Hence, the color intensities
(i.e., the color-spectrum representations of the cell-numbers) are comparable
over the respective heatmaps. Note that the column numbers should sum to
unity.
2.3.5. Node Characteristics. In addition to global metrics, we assess certain charac-
teristics of individual nodes within the topologies of interest, focusing especially on
the notion of centrality. Centrality, in general, refers to metrics regarding the most
central or (functionally) important nodes in a network. Several centrality measures
are used whose formal definition can be found in, e.g., [S2.12]: degree centrality,
betweenness centrality, closeness centrality, and eigenvalues centrality. Degree cen-
trality simply indicates the number of connections in which a node takes part. It
is indicative of the nodes that are central or influential in terms of the number of
connections: more connections could imply deeper regulatory influence. Between-
ness centrality [S2.16] measures centrality in terms of information flow. Under the
assumption that information is passed over short(est) paths a node becomes cen-
tral when the number of short(est) paths that pass through it is high. Closeness
centrality indicates the mean distance of a node to other nodes. A node is central
under the closeness centrality metric when it’s mean distance to other nodes is
low. Note that closeness as used here reflects the sum of inverse distances [S2.17],
such that nodes that are close to many other nodes receive high closeness scores.
The eigenvalue centrality [S2.12] is an extension of the degree centrality. A node’s
eigencentrality is based on the centrality of the nodes to which it is connected:
connections to central others are weighted more heavily in the final eigencentrality
score than connections to less central others. These various centrality scores thus
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have different flavors and may indicate correspondingly flavored hubs (i.e., highly
central nodes).
Figures S2.10 and S2.11 contain target plots [S2.18] depicting the various central-
ity properties of the metabolite compounds retained in the SCD and AD topologies.
The target plots were created with the help of the sna and igraph packages in R
[S2.19, S2.20, S2.21]. Tables S2.7 and S2.8 then contain, to accompany these fig-
ures, the top centrality metrics for the SCD and AD topologies, respectively. The
strongest hub in the SCD topology is the oxidative stress compound LPA C18:2.
This compound sorts the highest scores on all centrality measures. The top com-
pounds, in terms of centrality, in the SCD topology all belong to either the oxidative
stress or lipid family. Next to LPA C18:2, the Phosphatidylcholines PC(34:1) and
PC(36:2) are consistently represented as hubs by all centrality measures. LPA C18:2
is also the strongest hub compound in the AD topology. The top compounds, in
terms of centrality, of the AD topology indeed largely overlap with the top com-
pounds of the SCD topology. Although the same compound may be a hub in both
the AD and SCD topologies, it can still be wired very differently, i.e., it’s connec-
tions may differ greatly between the two topologies (see Section 2.3.6). In addition,
for the AD topology the amines Glycylglycine and Tyrosine are quite consistently
indicated as central compounds by the degree, betweenness, and closeness metrics.
Table S2.7. Centrality measures for the SCD topology.
Degree Betweenness Closeness Eigenvalue
LPA C18:2 9 LPA C18:2 483.00 LPA C18:2 .317 LPA C18:2 .415
PC(36:2) 7 TG(52:2) 454.06 TG(52:2) .295 PAF C16:0 .378
PAF C16:0 7 PC(36:3) 300.00 PAF C16:0 .279 LPA C16 .331
TG(50:2) 6 PC(36:2) 291.50 PC(36:2) .276 LPA C16:1 .315
TG(52:2) 6 Proline 220.00 PC(34:1) .274 PC(36:2) .271
PC(34:1) 6 TG(50:1) 202.00 TG(50:2) .274 PC(34:1) .238
LPA C16 6 PC(34:1) 180.85 LPA C16:1 .271 LPA C18:1 .237
LPA C16:1 6 Alanine 180.00 LPA C16 .270 LPC(16:0) .235
Table S2.8. Centrality measures for the AD topology.
Degree Betweenness Closeness Eigenvalue
LPA C18:2 9 LPA C18:2 661.87 LPA C18:2 .395 LPA C18:2 .353
PC(36:2) 8 TG(52:2) 533.69 TG(52:2) .359 PC(36:2) .331
TG(52:2) 7 Glycylglycine 328.92 PC(36:2) .345 LPA C20:4 .293
PC(36:4) 7 Tyrosine 249.87 Glycylglycine .336 PAF C16:0 .286
PAF C16:0 7 TG(50:1) 220.17 PC(36:4) .331 LPA C18:1 .284
Glycylglycine 6 PC(36:4) 194.85 PAF C16:0 .327 PC(36:4) .270
PC(34:1) 6 PC(36:2) 180.92 LPA C18:1 .325 PC(34:1) .248
LPA C16 6 L-Lactic acid 178.38 PC(34:1) .325 LPA C16 .218
LPA C20:4 6 PC(34:1) 173.10 Tyrosine .322 LPA C22:6 .211
2.3.6. Communities. The nodes in a network often cluster in groups: collections of
nodes that are more deeply connected to each other than to nodes outside their
topological environment. There is thus interest in the detection of these groups. We
approach the question of node-grouping from two angles. The first is the perspective
of k-cores. A k-core of a network is the maximal connected subnetwork in which all
nodes have a degree of at least k [S2.12]. In this setting, the k-core decomposition
of a topology is used as an indication of the core-periphery structure of a network.
Figure S2.12 contains the k-core decomposition of the SCD and AD topologies
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Figure S2.10. Target plots [S2.18] visualizing various centralities for the
network representing the SCD group. The upper-left panel represents degree
centralities. The upper-right panel represents betweenness centralities. The
lower-left panel represents closeness centralities. The lower-right panel repre-
sents eigenvalue centralities. Note that, for each target plot, the network is the
same as in the left-hand panel of Figure S2.7. The topology is now however
plotted to represent metabolite features according to various centrality scores.
For example, the oxidative stress compound LPA C18:2 has the highest degree
centrality and, hence, is depicted in the center of the upper-left panel. The
metabolite compounds are again colored according to metabolite family: Blue
for amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations. The metabolite features attaining the
highest centrality scores are given in Table S2.7.
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Figure S2.11. Target plots [S2.18] visualizing various centralities for the
network representing the AD group. The upper-left panel represents degree
centralities. The upper-right panel represents betweenness centralities. The
lower-left panel represents closeness centralities. The lower-right panel repre-
sents eigenvalue centralities. Note that, for each target plot, the network is the
same as in the right-hand panel of Figure S2.7. The topology is now however
plotted to represent metabolite features according to various centrality scores.
For example, the oxidative stress compound LPA C18:2 has the highest degree
centrality and, hence, is depicted in the center of the upper-left panel. The
metabolite compounds are again colored according to metabolite family: Blue
for amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations. The metabolite features attaining the
highest centrality scores are given in Table S2.8.
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depicted in the radial layout of a target plot [S2.18]. For both panels the center
represents the 3-core, the first ring of features around the center represents the 2-
core, and the subsequent feature-rings represent the 1-core and 0-core, respectively.
The k-cores of the SCD and AD topologies are similar, although the AD topology
places the amine Glycylglycine in the 2-core instead of the 1-core.
Figure S2.12. Target plots [S2.18] with the k-core decomposition of the
SCD (left-hand panel) and AD (right-hand panel) networks. Note that the
SCD and AD networks are the same as depicted in the panels of Figure S2.7.
The respective topologies are now however plotted to represent k-coreness.
The features in the middle of the radial layouts then represent features in the
graph-core while features that are plotted further from the center represent the
peripheral features. The metabolite compounds are again colored according
to metabolite family: Blue for amines, yellow for lipids, orange for organic
acids, and purple for oxidative stress. Solid edges represent positive partial
correlations while dashed edges represent negative partial correlations.
The second perspective on finding node-groupings is community detection. Com-
munity detection, loosely speaking, refers to the “search for naturally occurring
groups in a network” [S2.12, p. 371]. A betweenness-based method of community
detection is used, commonly known as the Girvan-Newman algorithm [S2.22]. Fig-
ure S2.13 contains the same networks as Figure S2.7, but now they are visualized
to express the community structure. The colored borders demarcate communities
within the respective topologies. Most notably, the SCD topology seems to have 2
loosely connected amine components while the AD topology seems to have a larger
and more densely connected amine component that has ties to oxidative stress
components.
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Figure S2.13. Class-specific semi-pruned networks visualized with the Fruchterman-Reingold algorithm and their community struc-
ture. The left-hand panel contains the network for the SCD group. The right-hand panel contains the network for the AD group. Solid
edges represent positive partial correlations while dashed edges represent negative partial correlations.
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2.3.7. Differential Graphs. Section 2.3.5 indicated that certain metabolites act as
hubs in both the SCD and AD topologies. Section 2.3.6 then indicated that these
hubs belong to different communities in the SCD and AD topologies. Thus, while
the SCD and AD topologies may contain the same hub-compounds, these com-
pounds may be connected very differently, implying differential regulatory func-
tioning in the respective networks. Hence, we take interest in the networks of
shared and differential connections over the SCD and AD topologies. Figure S2.14
depicts in the left-hand panel the connections that are shared between the SCD
and AD networks, and in the right-hand panel the connections that are unique
to either the SCD or the AD network. This figure is accompanied by Table S2.9,
which contains the top degrees for the differential network (right-hand panel of
Figure S2.14). These degrees indicate the compounds that are most differentially
wired between the SCD and AD topologies. We see that the regulatory functioning
(in terms of connections) of the oxidative stress compounds LPA C18:2 and PAF
C16:0 – central to both the SCD and AD topologies – is different across the SCD
and AD topologies. In addition, we see compounds that, although not central in
either the SCD or AD topologies, are central in the differential network, such as the
Phosphatidylcholine PC(38:6). Moreover, we see compounds whose wiring seems to
be unique to either the SCD or AD topologies. For example, the amine Glutamine
seems to be connected in the SCD topology mostly, while the amine Glycylglycine
seems mostly unique to the AD topology, in which it connects with other amines
and oxidative stress compounds. Overall, the most differentially wired metabolites
across the SCD and AD topologies belong predominantly to the Lyso-phosphatidic
acid oxidative stress compounds, the Phosphatidylcholines, and the amine family.
Table S2.9. Most differentially wired metabolic features in the
differential network for the SCD group versus the AD group.
Feature Compound class Degree
LPA C18:2 Oxidative stress: Lyso-phosphatidic acid 10
Glycylglycine Amines 6
PC(36:4) Lipids: Phosphatidylcholine 6
PC(38:6) Lipids: Phosphatidylcholine 6
LPA C16 Oxidative stress: Lyso-phosphatidic acid 6
PAF C16:0 Platelet activating factor 6
Glutamine Amines 5
LPA C18:1 Oxidative stress: Lyso-phosphatidic acid 5
LPA C20:4 Oxidative stress: Lyso-phosphatidic acid 5
Tyrosine Amines 4
LPA C16:1 Oxidative stress: Lyso-phosphatidic acid 4
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Figure S2.14. Common and differential networks for the SCD versus AD class. The left-hand panel contains the network consisting of
the edges (solid and colored blue) that are shared between the SCD and AD groups. The right-hand panel contains the network consisting
of the edges that are unique for either the SCD or the AD group. Red edges represent connections that are present in the AD group
only. Green edges represent connections that are present in the SCD group only. Solid edges represent positive partial correlations while
dashed edges represent negative partial correlations. The metabolite compounds are colored according to metabolite family: Blue for
amines, yellow for lipids, orange for organic acids, and purple for oxidative stress. Note that the nodes in these networks have coordinates
concordant with the node-placing of Figure S2.7.
24 F.A. DE LEEUW AND C.F.W. PEETERS ET AL.
2.4. Regulatory Signature: Including APOE 4 allele status.
2.4.1. Approach. In our graphical modeling approach we take into account that our
data consist of distinct classes of interest. In the preceding section we looked at
the first natural distinction: AD versus SCD. The second distinction is having no
APOE 4 allele versus having at least 1 APOE 4 allele. The APOE 4 indicator
proved influential in the classification signature. Moreover, having at least 1 APOE
4 allele is strongly associated with the AD disease label: The Fisher exact test on
Table S2.10 sorts a p-value of 1.553e-10, indicating that persons with AD are more
likely to have at least 1 APOE 4 allele. One may expect that AD with and AD
without the APOE 4 allele represent two (somewhat) distinct disease processes.
Moreover, one could expect that for a portion of the SCD cases that have at least
1 APOE 4 allele, certain metabolic changes indicative of looming AD may already
be present. In this situation we thus have four classes or groups of interest (Table
S2.10 gives the number of observations for each group).
Table S2.10. Number of observations in the cross-tabulation of
AD disease status and APOE 4 allele status.
At least 1 APOE 4 allele
No Yes
AD 40 87
SCD 87 34
The graphical modeling approach is analogous to the strategy described in Sec-
tion 2.3.2, but now we have g = 1, . . . , 4. We solve (S2.4) using the class-specific
sample covariance matrices (i.e., the sample covariance matrices of the class-specific
data) as the data entries. For the target T we again choose the (weakly informa-
tive) p-dimensional identity matrix Ip. The optimal penalty parameters were again
determined by LOOCV [S2.7]. The optimal penalty values were found to be λ∗ =
10.02109, and λ∗f = 3.970277e-17. These penalty values again emphasize individual
regularization over retainment of entry-wise similarities, indicating strong differ-
ences in class-specific precision matrices. For each class-specific matrix, the 100
strongest edges (in terms of absolute partial correlations) were retained. The re-
tained partial correlations range, in absolute value, from .1376073 to .5791377 over
the respective classes. All analyzes were again performed with the rags2ridges
package [S2.8] in R [S2.9].
2.4.2. Results. Here, we state all results for the the group-specific networks stem-
ming from the cross-tabulation of AD disease status APOE 4 allele status. For
detail on technical terms, see Section 2.3.
Figure S2.15 contains the class-specific pruned networks visualized with the FR
algorithm [S2.10]. Figures S2.16 and S2.17 then contain the class-specific networks
over the union of retained metabolites in which the FR-based coordinates of the
network of the SCD group with no APOE 4 allele serve as reference coordinates.
As stated, the FR algorithm prefers coiled structures. From this perspective the
network for the SCD group with no APOE 4 allele (SCD¬4) and the network for
the AD group with at least 1 APOE 4 allele (AD4) seem the most structured
ones. Perhaps this is natural for the former group, given that these persons are,
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in some sense, the least at risk for developing AD, and thus should represent the
normal biochemical state. This might also be natural for the latter group, as
this network may represent structured APOE 4-driven changes in metabolism.
The networks for the SCD group with at least 1 APOE 4 allele (SCD4) and
the AD group with no APOE 4 allele (AD¬4) appear more random, i.e., less
modular or locally connected. As stated, one could expect that for a portion of
the SCD4 group, certain metabolic changes indicative of looming AD may already
be present. Also, the AD¬4 group may represent various alternative AD disease
processes. In short, both these latter groups are likely heterogeneous. Table S2.11
then contains some global characteristics of each class-related graph as given in
Figures S2.16 and S2.17. These metrics corroborate to some degree the assessment
made above: The topology for the SCD¬4 group is most strongly locally connected,
and the topologies for the SCD¬4 group and the AD4 group are most cohesive
(overall). Figures S2.18 and S2.19 also indicate that the topologies for the SCD4
group and the AD¬4 group are more diffuse. Moreover, they indicate that the
topology for the AD4 group can be characterized (vis-a`-vis the SCD¬4 topology)
by increased connection density within the amine compounds and between the
amine and oxidative stress compounds.
Table S2.11. Global metrics for the four topologies of interest.
Topology Transitivity Connectedness Centralization
SCD group with no APOE 4 allele .2136986 .7134809 .1055901
SCD group with at least 1 APOE 4 allele .142315 .6201207 .1496894
AD group with no APOE 4 allele .1758621 .5758551 .1937888
AD group with at least 1 APOE 4 allele .1480519 .7126761 .1496894
Figures S2.20, S2.21, S2.22, and S2.23 contain target plots depicting the various
centrality properties of the metabolite compounds retained in the SCD¬4, SCD4,
AD¬4, and AD4 topologies, respectively. Tables S2.13, S2.14, S2.15, and S2.16
then contain the top centrality metrics for these topologies. The top compounds, in
terms of centrality, in the SCD¬4 topology, all belong to either the oxidative stress
or lipid family. The SCD4 and AD¬4 topologies are indeed, as also indicated in
Table S2.11, more centralized, having more compounds with a high degree. The
centrality picture for these topologies is more diffuse in terms of compound-families
(i.e., all compound families are represented). The top compounds in the AD4
topology largely overlap with the to compounds of the SCD¬4 topology. However,
AD4 topology the amines Glycylglycine and Tyrosine are consistently indicated as
central compounds by all centrality measures. Interestingly, these amines are also
consistently marked as central in the SCD4 topology.
Figure S2.24 depicts the k-core decomposition of the topologies of interest. The
inner-core of the SCD¬4 topology consists exclusively of lipid and oxidative stress
compounds. The inner-core of the AD4 topology includes the amines Glycylglycine,
Tyrosine, Isoleucine, Threonine, and Valine. The inner-cores of the SCD4 and
AD¬4 topologies include metabolites from all compound-families and are thus less
compound-family centered. Figure S2.25 contains the SCD¬4 and SCD4 topolo-
gies visualized with their community structure. Figure S2.26 then contains the
AD¬4 and AD4 topologies visualized with their community structure. The col-
ored borders demarcate communities within the respective topologies. The SCD¬4
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and AD4 topologies are indeed the most modular ones. The SCD¬4 has clear
organic acid, triglyceride, Phosphatidylcholine, and amine communities. The Lyso-
phosphatidic acids (oxidative stress compounds) largely form a community with
the Phosphatidylcholines. It contains 2 loosely connected amine communities. The
AD4 topology, on the other hand, seems to have larger and more densely con-
nected amine communities that include organic acid compounds and that have ties
to oxidative stress compounds.
The SCD¬4 and AD4 topologies represent the most structured graphs. More-
over, they represent (relatively) homogenous groups (in terms of AD pathology).
In assessing differential graph structures, we thus focus on these two topologies.
Figure S2.27 then contains in the left-hand panel the network of shared connec-
tions and in the right-hand panel the network of unique connections between the
SCD¬4 and AD4 groups. Table S2.12 then contains a list of metabolites with the
highest degrees in the differential network (right-hand panel of S2.27). These dif-
ferential degrees indicate the metabolites that change their regulatory function (in
terms of differential connections) the most between the SCD¬4 and AD4 groups.
Overall, the most differentially wired metabolites across their topologies belong ex-
clusively to the oxidative stress and amine compound-families. The oxidative stress
compound LPA C18:2 is well-connected in both the SCD¬4 and AD4 topologies,
but is wired very differently between them. From this perspective LPA C18:2 is
implied in the loss of normal and the gain of abnormal connections in the AD state
driven by APOE 4. The oxidative stress compound PAF C16:0 seems to be well-
connected in the SCD¬4 group mostly. Hence, this compound is implied in the
loss of normal regulatory connections in the AD state driven by APOE 4. The
amine Glycylglycine seems to be well-connected in the AD4 group mostly. This
compound is thus implied in the gain of abnormal regulatory connections in the AD
state driven by APOE 4. These connections are amongst amines predominantly.
This latter observation also, to a lesser degree, holds for the amines Tyrosine and
Glutamine.
Table S2.12. Most differentially wired metabolic features in the
differential network for the SCD group with no APOE 4 allele
versus the AD group with at least 1 APOE 4 allele.
Feature Compound class Degree
LPA C18:2 Oxidative stress: Lyso-phosphatidic acid 13
Glycylglycine Amines 11
Tyrosine Amines 8
PAF C16:0 Oxidative stress: Platelet activating factor 8
Glutamine Amines 7
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Figure S2.15. Class-specific pruned networks visualized with the
Fruchterman-Reingold algorithm. The upper-left panel contains the network
for the SCD group with no APOE 4 allele. The upper-right panel contains
the network for the SCD group with at least 1 APOE 4 allele. The lower-
left panel represents the network for the AD group with no APOE 4 allele.
The lower-right panel represents the network for the AD group with at least 1
APOE 4 allele. The metabolite compounds are colored according to metabo-
lite family: Blue for amines, yellow for lipids, orange for organic acids, and
purple for oxidative stress. Solid edges represent positive partial correlations
while dashed edges represent negative partial correlations. Appears as Figure
3 in the main text.
2
8
F
.A
.
D
E
L
E
E
U
W
A
N
D
C
.F
.W
.
P
E
E
T
E
R
S
E
T
A
L
.
Figure S2.16. Class-specific semi-pruned networks visualized with the Fruchterman-Reingold algorithm. The left-hand panel contains
the network for the SCD group with no APOE 4 allele. The right-hand panel contains the network for the SCD group with at least 1
APOE 4 allele. The coordinates of the left-hand topology serve as the reference coordinates. The metabolite compounds are colored
according to metabolite family: Blue for amines, yellow for lipids, orange for organic acids, and purple for oxidative stress. Solid edges
represent positive partial correlations while dashed edges represent negative partial correlations.
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Figure S2.17. Class-specific semi-pruned networks visualized with the Fruchterman-Reingold algorithm. The left-hand panel contains
the network for the AD group with no APOE 4 allele. The right-hand panel contains the network for the AD group with at least 1 APOE
4 allele. The coordinates of the left-hand topology in Figure S2.16 serve as the reference coordinates. The metabolite compounds are
colored according to metabolite family: Blue for amines, yellow for lipids, orange for organic acids, and purple for oxidative stress. Solid
edges represent positive partial correlations while dashed edges represent negative partial correlations.
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Figure S2.18. Heatmaps of degree densities for the class-specific net-
works. The reported numbers represent the degree density for the (combi-
nations of) metabolite groups. Degree density represents the number of con-
nections (edges) divided by the number of possible connections. For example,
in the network for the SCD group with no APOE 4 allele the proportion of
actual edges relative to the number of possible edges between Amines and ox-
idative stress compounds is .0343. Note that all heatmaps received the same
color key. Hence, the color intensities (i.e., the color-spectrum representations
of the cell-numbers) are comparable over the respective heatmaps.
BLOOD-BASED METABOLIC SIGNATURES IN ALZHEIMER’S DISEASE 31
0.5294
0
0.0588
0.4118
0
0.7119
0
0.2881
0.1429
0
0.4286
0.4286
0.1556
0.3778
0.0667
0.4Oxidative Stress
Organic Acids
Lipids
Amines
Am
ines
Lipids
O
rganic Acids
O
xidative
 Stress
 
 
0.0
0.2
0.4
0.6
SCD Group, No APOE E4 Allele
0.413
0.2174
0.1087
0.2609
0.2083
0.4375
0.0208
0.3333
0.4167
0.0833
0.25
0.25
0.2927
0.3902
0.0732
0.2439Oxidative Stress
Organic Acids
Lipids
Amines
Am
ines
Lipids
O
rganic Acids
O
xidative
 Stress
 
 
0.0
0.2
0.4
0.6
SCD Group, at least 1 APOE E4 Allele
0.4194
0.0968
0.129
0.3548
0.0577
0.5192
0.0385
0.3846
0.3077
0.1538
0.1538
0.3846
0.2245
0.4082
0.102
0.2653Oxidative Stress
Organic Acids
Lipids
Amines
Am
ines
Lipids
O
rganic Acids
O
xidative
 Stress
 
 
0.0
0.2
0.4
0.6
AD Group, No APOE E4 Allele
0.5357
0.0714
0.0714
0.3214
0.0333
0.65
0
0.3167
0.4
0
0.4
0.2
0.225
0.475
0.025
0.275Oxidative Stress
Organic Acids
Lipids
Amines
Am
ines
Lipids
O
rganic Acids
O
xidative
 Stress
 
 
0.0
0.2
0.4
0.6
AD Group, at least 1 APOE E4 Allele
Figure S2.19. Heatmaps of relative outdegrees for the class-specific net-
works. The reported numbers represent the relative outdegree for the (combi-
nations of) metabolite groups. The relative outdegree represents the number
of connections (edges) between two metabolite groups divided by the number
of ‘outgoing’ connections for one of these groups. For example, in the network
for the SCD group with no APOE 4 allele the number of edges between lipid
and oxidative stress compounds accounts for approximately 29% of all edges
involving lipids and approximately 38% of all edges involving oxidative stress
compounds. Note that all heatmaps received the same color key. Hence, the
color intensities (i.e., the color-spectrum representations of the cell-numbers)
are comparable over the respective heatmaps. Note that the column numbers
sum to unity.
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Figure S2.20. Target plots visualizing various centralities for the network
representing the SCD group with no APOE 4 allele. The upper-left panel
represents degree centralities. The upper-right panel represents betweenness
centralities. The lower-left panel represents closeness centralities. The lower-
right panel represents eigenvalue centralities. Note that, for each target plot,
the network is the same as in the left-hand panel of S2.16. The topology
is now however plotted to represent metabolite features according to various
centrality scores. For example, the oxidative stress compounds LPA.C18.2 and
PAF.C16.0 have the highest degree centrality and, hence, are depicted in the
center of the upper-left panel. The metabolite compounds are again colored
according to metabolite family: Blue for amines, yellow for lipids, orange for
organic acids, and purple for oxidative stress. Solid edges represent positive
partial correlations while dashed edges represent negative partial correlations.
The metabolite features attaining the highest centrality scores are given in
Table S2.13.
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Figure S2.21. Target plots visualizing various centralities for the network
representing the SCD group with at least 1 APOE 4 allele. The upper-left
panel represents degree centralities. The upper-right panel represents between-
ness centralities. The lower-left panel represents closeness centralities. The
lower-right panel represents eigenvalue centralities. Note that, for each target
plot, the network is the same as in the right-hand panel of S2.16. The topology
is now however plotted to represent metabolite features according to various
centrality scores. For example, the Amine Glycylglycine has the highest degree
centrality and, hence, it is depicted in the center of the upper-left panel. The
metabolite compounds are again colored according to metabolite family: Blue
for amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations. The metabolite features attaining the
highest centrality scores are given in Table S2.14.
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Figure S2.22. Target plots visualizing various centralities for the network
representing the AD group with no APOE 4 allele. The upper-left panel
represents degree centralities. The upper-right panel represents betweenness
centralities. The lower-left panel represents closeness centralities. The lower-
right panel represents eigenvalue centralities. Note that, for each target plot,
the network is the same as in the left-hand panel of S2.17. The topology
is now however plotted to represent metabolite features according to various
centrality scores. For example, the Amine Glycylglycine has the highest degree
centrality and, hence, it is depicted in the center of the upper-left panel. The
metabolite compounds are again colored according to metabolite family: Blue
for amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations. The metabolite features attaining the
highest centrality scores are given in Table S2.15.
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Figure S2.23. Target plots visualizing various centralities for the network
representing the AD group at least 1 APOE 4 allele. The upper-left panel
represents degree centralities. The upper-right panel represents betweenness
centralities. The lower-left panel represents closeness centralities. The lower-
right panel represents eigenvalue centralities. Note that, for each target plot,
the network is the same as in the right-hand panel of S2.17. The topology
is now however plotted to represent metabolite features according to vari-
ous centrality scores. For example, the oxidative stress compound LPA.C18.2
has the highest degree centrality and, hence, it is depicted in the center of
the upper-left panel. The metabolite compounds are again colored according
to metabolite family: Blue for amines, yellow for lipids, orange for organic
acids, and purple for oxidative stress. Solid edges represent positive partial
correlations while dashed edges represent negative partial correlations. The
metabolite features attaining the highest centrality scores are given in Table
S2.16.
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Table S2.13. Centrality measures for the SCD group with no
APOE 4 allele.
Degree Betweenness Closeness Eigenvalue
LPA C18:2 10 PAF C16:0 585.19 PAF C16:0 0.416 LPA C18:2 .405
PAF C16:0 10 LPA C20:4 507.93 LPA C18:2 0.406 PAF C16:0 .376
TG(50:2) 7 LPA C18:2 409.96 LPA C16 0.379 LPA C16 .330
PC(34:1) 7 PC(34:1) 363.92 PC(34:1) 0.375 LPA C18:1 .270
LPA C16 7 Tyrosine 248.58 LPA C20:4 0.371 LPA C20:4 .254
LPA C20:4 7 LPA C22:6 243.67 TG(52:2) 0.354 PC(34:1) .245
TG(52:2) 6 LPA C16 232.80 LPA C18:1 0.348 PC(36:2) .233
Table S2.14. Centrality measures for the SCD group with at
least 1 APOE 4 allele.
Degree Betweenness Closeness Eigenvalue
Glycylglycine 13 Glycylglycine 365.75 Glycylglycine .443 Glycylglycine .360
LPA C18:2 12 LPA C18:2 305.64 LPA C18:2 .429 Tyrosine .346
PAF C16:0 12 TG(52:2) 294.73 Tyrosine .427 LPA C18:2 .290
Tyrosine 11 Phenylalanine 292.56 Phenylalanine .419 PAF C16:0 .281
Phenylalanine 9 Tyrosine 267.47 TG(52:2) .411 Phenylalanine .279
L-Lactic acid 9 PAF C16:0 241.17 PAF C16:0 .410 Glutamine .272
TG(52:2) 9 L-Lactic acid 166.26 Glutamine .394 TG(52:2) .255
Glutamine 7 SPH C18:1 140.86 L-Lactic acid .381 L-Lactic acid .209
PC(36:2) 6 TG(50:2) 120.13 PC(36:2) .368 PC(36:2) .204
SPH C18:1 6 Glutamine 111.86 SPH C18:1 .354 SPH C18:1 .184
Table S2.15. Centrality measures for the AD group with no
APOE 4 allele.
Degree Betweenness Closeness Eigenvalue
Glycylglycine 16 Glycylglycine 418.71 Glycylglycine .455 LPA C18:2 .369
LPA C18:2 14 LPA C18:2 376.70 LPA C18:2 .446 Glycylglycine .356
L-Lactic acid 12 PC(34:2) 319.04 PC(34:2) .436 PC(34:2) .353
PC(34:2) 12 TG(52:2) 250.23 L-Lactic acid .419 L-Lactic acid .331
PAF C16:0 10 L-Lactic acid 216.33 PAF C16:0 .405 PAF C16:0 .288
Tyrosine 6 PC(34:1) 184.65 PC(34:1) .367 SPH C18:1 .196
TG(52:2) 6 PAF C16:0 165.12 SPH C18:1 .360 LPA C16 .189
PC(34:1) 6 TG(50:1) 103.00 LPA C16 .348 PC(34:1) .178
PC(38:6) 6 SM(d18:1/16:0) 102.00 LPA C20:4 .348 LPA C20:4 .167
SPH C18:1 6 LPA C18:1 78.31 PC(38:6) .342 PC(38:6) .161
LPA C16 6 SPH C18:1 77.82 Tyrosine .339 S1P C18:1 .158
Table S2.16. Centrality measures for the AD group with at least
1 APOE 4 allele.
Degree Betweenness Closeness Eigenvalue
LPA C18:2 13 LPA C18:2 682.98 LPA C18:2 .452 LPA C18:2 .473
Glycylglycine 9 TG(52:2) 537.91 Glycylglycine .399 LPA C20:4 .336
Tyrosine 7 Glycylglycine 388.77 TG(52:2) .398 Glycylglycine .279
TG(52:2) 7 TG(50:1) 232.91 LPA C20:4 .385 PC(36:4) .236
PC(34:1) 7 PC(34:1) 231.83 Tyrosine .363 PC(36:2) .230
LPA C20:4 7 Tyrosine 231.23 PC(34:1) .354 LPA C18:1 .218
PC(36:4) 6 PC(36:4) 217.96 PC(36:4) .354 Tyrosine .211
PAF C16:0 6 PC(34:2) 179.58 Valine .349 Valine .206
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Figure S2.24. Target plots [S2.18] depicting k-core decompositions. The
upper-left panel contains the network for the SCD group with no APOE 4
allele. The upper-right panel contains the network for the SCD group with at
least 1 APOE 4 allele. The lower-left panel represents the network for the AD
group with no APOE 4 allele. The lower-right panel represents the network
for the AD group with at least 1 APOE 4 allele. Note that the respective
topologies are now plotted to represent coreness. The features in the middle of
the radial layouts then represent features in the graph-core while features that
are plotted further from the center then represent the peripheral features. The
metabolite compounds are again colored according to metabolite family: Blue
for amines, yellow for lipids, orange for organic acids, and purple for oxidative
stress. Solid edges represent positive partial correlations while dashed edges
represent negative partial correlations.
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Figure S2.25. Class-specific semi-pruned networks visualized with their community structure. The left-hand panel contains the
network for the SCD group with no APOE 4 allele. The right-hand panel contains the network for the SCD group with at least 1 APOE
4 allele. Solid edges represent positive partial correlations while dashed edges represent negative partial correlations.
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Figure S2.26. Class-specific semi-pruned networks visualized with their community structure. The left-hand panel contains the
network for the AD group with no APOE 4 allele. The right-hand panel contains the network for the AD group with at least 1 APOE 4
allele. Solid edges represent positive partial correlations while dashed edges represent negative partial correlations.
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Figure S2.27. Common and differential networks for the SCD group with no APOE 4 allele versus the AD group with at least 1
APOE 4 allele. The left-hand panel contains the network consisting of the edges (solid and colored blue) that are shared between these
groups. The right-hand panel contains the network consisting of the edges that are unique for either of the groups. Red edges represent
connections that are present in the AD group with at least 1 APOE 4 allele only. Green edges represent connections that are present
in the SCD group with no APOE 4 allele only. Solid edges represent positive partial correlations while dashed edges represent negative
partial correlations. The metabolite compounds are colored according to metabolite family: Blue for amines, yellow for lipids, orange for
organic acids, and purple for oxidative stress. Note that the nodes in these networks have coordinates concordant with the node-placing of
Figure S2.16. Appears as Figure 4 in the main text.
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SUPPLEMENTARY TEXT 3
Basic Results on all Cases
This supplementary text presents, for purposes of comparison, basic informa-
tion on the obtained expression and classification signatures when considering data
from all patients. That is, patients whose clinical diagnosis was discordant from
their CSF-biomarker status were not excluded from the analyzes described below.
Processing of the data was analogous to the steps described in Section 2.4 of the
main text and Section 1.2 of Supplementary Text 2. Again, metabolites with more
than 10% missing observations were removed, leading to the removal of the same 5
metabolites mentioned in Section 1.2 of Supplementary Text 2. Also, again three
data samples were removed as their (plasma) quality was deemed unsure and an ad-
ditional twelve data samples were removed due to instrumental errors in one or more
MS platforms. The final metabolic data set for the analyzes below thus contained
n = 285 data samples (141 AD and 144 SCD) and p = 230 metabolic features.
Section 1 contains information on the differential expression signature. Section 2
then contains information on the classification signature. Section 3 concludes with
some reflections on the findings.
1. Differential Expression Signature
The approach for the evaluation of differential metabolic expression between AD
and SCD subjects was described in Section 2.1.1 of Supplementary Text 2. The
list of metabolic features that survive multiple testing correction when only sex
and age are used as possible confounders can be found in Table S3.1. Table S3.2
then contains the list of metabolic features that survive multiple testing correction
when correcting for all clinical variables of interest (see Table 1 of the main text).
All compounds in the latter table appear to be underexpressed in the AD group
relative to the control group, expect for the Sphingomyelin SM(d18:1/20:1).
2. Classification Signature
The approach for the construction of classification signatures was described in in
Section 2.2.1 of Supplementary Text 2. Model performances can be found in Figure
S3.1. The prediction model carrying the clinical variables only resulted in an AUC
of .695. The model that used the Lasso for selection amongst the metabolites sorts
a somewhat better classification performance, yielding an AUC of .746. The model
that adds a (Lasso-based) selection of metabolites to the clinical variables then
improves predictive performance along the full false positive rate range, sorting a
AUC of .796. Table S3.3 contains the metabolites selected in the selection-amongst-
metabolites-only situation. Table S3.4 then contains the metabolites selected in the
selection-amongst-metabolites-whilst-clinical-variables-present situation. We see,
for the compounds that also occur in the differential expression signature, that
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Table S3.1. Differentially expressed metabolites when correcting
for sex and age only.
Metabolite Compound class p-value Adjusted p-value
2-Aminoadipic acid Amines 6.085903e-08 1.399758e-05
Methyldopa Amines 2.583401e-07 2.970911e-05
Valine Amines 6.498148e-07 4.981913e-05
Tyrosine Amines 1.697832e-06 9.762531e-05
Lysine Amines 1.101781e-05 5.068193e-04
S-3-Hydroxyisobutyric acid Organic acids 2.749051e-05 1.053803e-03
TG(54:6) Lipids: Triglycerides 5.209223e-05 1.539997e-03
TG(48:0) Lipids: Triglycerides 5.356511e-05 1.539997e-03
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane 7.698703e-05 1.967446e-03
TG(50:4) Lipids: Triglycerides 8.835841e-05 2.032243e-03
Methylmalonic acid Organic acids 1.000548e-04 2.092055e-03
TG(52:4) Lipids: Triglycerides 1.316578e-04 2.523440e-03
TG(48:2) Lipids: Triglycerides 1.728144e-04 2.798978e-03
TG(50:3) Lipids: Triglycerides 1.761190e-04 2.798978e-03
Leucine Amines 1.825420e-04 2.798978e-03
TG(56:8) Lipids: Triglycerides 2.126884e-04 2.886597e-03
TG(51:3) Lipids: Triglycerides 2.317948e-04 2.886597e-03
TG(50:1) Lipids: Triglycerides 2.324632e-04 2.886597e-03
TG(48:3) Lipids: Triglycerides 2.384581e-04 2.886597e-03
TG(52:5) Lipids: Triglycerides 2.827883e-04 3.182738e-03
TG(50:2) Lipids: Triglycerides 2.905978e-04 3.182738e-03
TG(46:2) Lipids: Triglycerides 3.557556e-04 3.610453e-03
TG(48:1) Lipids: Triglycerides 3.610453e-04 3.610453e-03
TG(50:0) Lipids: Triglycerides 4.318757e-04 4.138809e-03
TG(52:3) Lipids: Triglycerides 5.484129e-04 5.045398e-03
TG(56:7) Lipids: Triglycerides 8.909861e-04 7.881800e-03
Isoleucine Amines 9.404737e-04 8.011442e-03
PGD2 Oxidative stress: Prostaglandins 9.789025e-04 8.040984e-03
LPC(18:1) lipids: Lysophosphatidylcholine 1.210008e-03 9.506953e-03
TG(52:1) Lipids: Triglycerides 1.240037e-03 9.506953e-03
SM(d18:1/20:1) Lipids: Sphingomyelins 1.592411e-03 1.176462e-02
1-Methylhistidine Amines 1.636817e-03 1.176462e-02
5-iPF2a VI Oxidative stress: Isoprostane 2.014948e-03 1.404357e-02
2-hydroxybutyric acid Organic acids 2.242011e-03 1.506750e-02
TG(54:5) Lipids: Triglycerides 2.292880e-03 1.506750e-02
SM(d18:1/23:0) Lipids: Sphingomyelins 2.583397e-03 1.607458e-02
TG(51:1) Lipids: Triglycerides 2.639813e-03 1.607458e-02
TG(58:10) Lipids: Triglycerides 2.655801e-03 1.607458e-02
TG(51:2) Lipids: Triglycerides 2.892979e-03 1.706116e-02
TG(46:1) Lipids: Triglycerides 3.683727e-03 2.118143e-02
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid 4.021010e-03 2.255689e-02
3-Hydroxyisovaleric acid Organic acids 4.778686e-03 2.616899e-02
TG(58:9) Lipids: Triglycerides 5.031803e-03 2.691430e-02
Histidine Amines 6.498831e-03 3.397116e-02
DG(36:3) Lipids: Diacylglycerol 7.216737e-03 3.688554e-02
Phenylalanine Amines 7.730540e-03 3.812873e-02
TG(52:2) Lipids: Triglycerides 7.791523e-03 3.812873e-02
SM(d18:1/24:2) Lipids: Sphingomyelins 8.365093e-03 4.008274e-02
PC(O-44:5) Lipids: Plasmalogen Phosphatidylcholine 8.717054e-03 4.091679e-02
8,12-iPF2a IV Oxidative stress: Isoprostane 9.768359e-03 4.493445e-02
TG(46:0) Lipids: Triglycerides 1.042619e-02 4.702009e-02
Methionine Amines 1.133966e-02 4.952164e-02
LPA C20:1 Oxidative stress: Lyso-phosphatidic acid 1.141151e-02 4.952164e-02
the signs of their effects concur with the pattern of AD-associated under- and
overexpression.
3. Some Reflections
Of the 285 subjects included in the analyzes above a total of 37 had a CSF-
biomarker status discordant with their clinical diagnosis. That is, these subjects
were either clinically diagnosed with AD while their CSF-markers were normal
(t-tau/Aβ42 ≤ 0.52) or clinically diagnosed as normal while their CSF-markers
indicated AD (t-tau/Aβ42 > 0.52). The disease status of these subjects is thus
unsure as it is unclear which diagnosis (clinical or biomarker-based) should take
precedence. Hence, the main analyzes revolved around those cases in which the
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Table S3.2. Differentially expressed metabolites when correcting
for all clinical variables.
Metabolite Compound class p-value Adjusted p-value
Tyrosine Amines 1.293884e-05 0.001941711
2-Aminoadipic acid Amines 2.118905e-05 0.001941711
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane 2.647672e-05 0.001941711
Methyldopa Amines 3.376889e-05 0.001941711
TG(54:6) Lipids: Triglycerides 7.936780e-05 0.003650919
TG(56:8) Lipids: Triglycerides 1.064855e-04 0.003864998
Valine Amines 1.176304e-04 0.003864998
TG(50:4) Lipids: Triglycerides 1.415809e-04 0.004070451
S-3-Hydroxyisobutyric acid Organic acids 2.261572e-04 0.005413816
TG(52:4) Lipids: Triglycerides 2.353833e-04 0.005413816
TG(51:3) Lipids: Triglycerides 2.779465e-04 0.005697531
PGD2 Oxidative stress: Prostaglandins 2.972625e-04 0.005697531
Lysine Amines 3.235788e-04 0.005724855
TG(52:5) Lipids: Triglycerides 3.734782e-04 0.005825832
TG(56:7) Lipids: Triglycerides 3.799456e-04 0.005825832
TG(48:3) Lipids: Triglycerides 4.059878e-04 0.005836075
TG(50:3) Lipids: Triglycerides 6.422663e-04 0.008689485
TG(46:2) Lipids: Triglycerides 8.831594e-04 0.011284814
TG(52:3) Lipids: Triglycerides 9.803097e-04 0.011866907
TG(58:10) Lipids: Triglycerides 1.166642e-03 0.013416381
SM(d18:1/23:0) Lipids: Sphingomyelins 1.259544e-03 0.013795004
TG(48:2) Lipids: Triglycerides 1.442328e-03 0.014514992
TG(58:9) Lipids: Triglycerides 1.451499e-03 0.014514992
TG(48:0) Lipids: Triglycerides 1.516374e-03 0.014531917
5-iPF2a VI Oxidative stress: Isoprostane 1.584192e-03 0.014574562
SM(d18:1/20:1) Lipids: Sphingomyelins 1.899763e-03 0.016805592
Methylmalonic acid Organic acids 2.206887e-03 0.018156831
3-Hydroxyisovaleric acid Organic acids 2.210397e-03 0.018156831
Ornithine Amines 3.068127e-03 0.024137545
TG(50:2) Lipids: Triglycerides 3.148375e-03 0.024137545
Leucine Amines 3.330067e-03 0.024706952
TG(54:5) Lipids: Triglycerides 3.448227e-03 0.024784134
DG(36:3) Lipids: Diacylglycerol 3.614235e-03 0.025190125
TG(48:1) Lipids: Triglycerides 3.740068e-03 0.025300461
TG(50:0) Lipids: Triglycerides 3.923739e-03 0.025784569
Phenylalanine Amines 4.059826e-03 0.025937777
TG(50:1) Lipids: Triglycerides 4.237719e-03 0.026342577
O-Acetylserine Amines 4.959665e-03 0.030019024
8,12-iPF2a IV Oxidative stress: Isoprostane 5.360289e-03 0.031324259
TG(51:2) Lipids: Triglycerides 5.447697e-03 0.031324259
SM(d18:1/25:0) Lipids: Sphingomyelins 7.146770e-03 0.039619151
NO2-aLA (C18:3) Oxidative stress: Nitro-Fatty acid 7.234801e-03 0.039619151
LPA C18 Oxidative stress: Lyso-phosphatidic acid 7.416156e-03 0.039667810
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid 8.866032e-03 0.046345167
clinical and biomarker-based diagnoses were concordant. Below we reflect on the
findings above in relation to the main analyzes.
The larger sample size implies that we have more power in finding differentially
expressed metabolites. Hence, Tables S3.1 and S3.2 list more metabolites than their
corresponding tables in Supplementary Text 2 (S2.3 and S2.2 ) and the Main text
(Table 3). As the increase in power comes from subjects whose disease status is
somewhat unsure, the results in Tables S3.1 and S3.2 are somewhat tentative. These
results are, however, concordant with the results from the main analyzes, in the
sense that they overlap, i.e.: The metabolites listed in Table S2.3 of Supplementary
Text 2 (see also column 3 of Table 3 of the Main text) are a proper subset (except for
Proline, PC(O-34:1), LPC(20:4), SM(18:1/16:0), and Ornithine) of the metabolites
listed in Table S3.1; and the metabolites listed in Table S2.2 of Supplementary
Text 2 (see also column 4 of Table 3 of the Main text) are a proper subset of the
metabolites listed in Table S3.2.
The main model of interest – selecting metabolites on top of clinical predictors
– has a concordant performance on the full and CSF-confirmed data: in both
instances the model sorts an AUC of approximately .79. Moreover, most of the
(top) compounds in Table S2.5 of Supplementary Text 2 appear as selected (top)
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Figure S3.1. ROC curves for the classification models. The grey line
represents the ROC curve for the unpenalized logistic regression model that
entertains the clinical characteristics only. The red line represents the ROC
curve for the logistic model in which the Lasso performed variable selection
amongst the metabolites (and that does not consider the clinical characteris-
tics). The blue line represents the ROC curve of the logistic model in which
the clinical characteristics are present while the Lasso may select amongst the
metabolites.
compounds in Table S3.4. The insecurity regarding the status of subjects with
discordant diagnoses is, however, reflected somewhat in the classification signatures.
For example, if we would take, for the main model of interest, the logistic cut-off at
the optimal cut-off in terms of accuracy (.42, as determined by 10-fold CV), then we
see that those clinically diagnosed with AD while having a normal CSF-status (14)
tend to be predominantly classified as AD cases while those clinically diagnosed
as normal while having an AD CSF-status (23) seem to be randomly classified as
either AD or control cases.
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Table S3.3. Selected metabolites and parameter estimates when
considering only metabolites as potential predictors.
Metabolite Compound class βˆ
LPC(18:1) lipids: Lysophosphatidylcholine 0.3775846437
Methyldopa Amines −0.3280999265
PGD2 Oxidative stress: Prostaglandins −0.3136491690
NO2-aLA (C18:3) Oxidative stress: Nitro-Fatty acid −0.2042163853
O-Acetylserine Amines −0.1811852503
SM(d18:1/23:0) Lipids: Sphingomyelins −0.1711821392
Tyrosine Amines −0.1588698635
SM(d18:1/20:1) Lipids: Sphingomyelins 0.1375561855
5-iPF2a VI Oxidative stress: Isoprostane −0.1296136239
Glyceric acid Organic acids −0.1271578713
PC(O-34:3) Lipids: Plasmalogen Phosphatidylcholine −0.1154877989
TG(54:6) Lipids: Triglycerides −0.1099736486
8,12-iPF2a IV Oxidative stress: Isoprostane −0.1091228644
Methylmalonic acid Organic acids −0.1021936840
TG(48:2) Lipids: Triglycerides −0.0880997011
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane −0.0859696149
LPA C16 Oxidative stress: Lyso-phosphatidic acid −0.0712895571
2,3-dinor-8-iso-PGF2a Oxidative stress: Isoprostane −0.0660850151
TG(O-50:0) Lipids: Triglycerides 0.0631492242
TG(48:0) Lipids: Triglycerides −0.0594940757
PC(O-38:6) Lipids: Plasmalogen Phosphatidylcholine −0.0573684699
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid −0.0462058983
Serine Amines 0.0427658066
Putrescine Amines −0.0402777537
LPA C22:4 Oxidative stress: Lyso-phosphatidic acid 0.0336067651
Lysine Amines −0.0308966941
3-Methoxytyramine Amines −0.0171013575
cLPA C18:1 Oxidative stress: Cyclic-lyso-phosphatidic acid −0.0127374834
PE(O-38:5) Lipids: Plasmalogen Phosphatidylethanolamine −0.0079640017
2-Aminoadipic acid Amines −0.0069680882
Carnosine Amines 0.0022778247
LPC(20:4) Lipids: Lysophosphatidylcholine 0.0006342159
Table S3.4. Selected metabolites and parameter estimates when
considering metabolites as potential predictors on top of the clini-
cal variables.
Metabolite Compound class βˆ
PGD2 Oxidative stress: Prostaglandins -0.48204926
SM(d18:1/20:1) Lipids: Sphingomyelins 0.33329421
O-Acetylserine Amines -0.28384663
Methyldopa Amines -0.27782490
8-iso-PGF2a (15-F2t-IsoP) Oxidative stress: Isoprostane -0.25085235
NO2-aLA (C18:3) Oxidative stress: Nitro-Fatty acid -0.24269712
Methylmalonic acid Organic acids -0.22969766
Tyrosine Amines -0.17320260
TG(52:4) Lipids: Triglycerides -0.15033254
Gamma-glutamylalanine Amines 0.13963417
Putrescine Amines -0.13769196
8,12-iPF2a IV Oxidative stress: Isoprostane -0.13656275
TG(51:3) Lipids: Triglycerides -0.13258986
SM(d18:1/23:0) Lipids: Sphingomyelins -0.11398902
Citrulline Amines -0.10005829
Glyceric acid Organic acids -0.09690281
LPC(18:1) lipids: Lysophosphatidylcholine 0.09252004
PC(O-34:3) Lipids: Plasmalogen Phosphatidylcholine -0.09149649
3-Hydroxyisovaleric acid Organic acids -0.08574230
5-iPF2a VI Oxidative stress: Isoprostane -0.08026972
LPA C14:0 Oxidative stress: Lyso-phosphatidic acid -0.07726029
2,3-dinor-8-iso-PGF2a Oxidative stress: Isoprostane -0.07467916
TG(58:10) Lipids: Triglycerides -0.06409276
Cysteine Amines 0.04297397
Carnosine Amines 0.03408938
PC(O-34:2) Lipids: Plasmalogen Phosphatidylcholine -0.03066565
SM(d18:1/25:0) Lipids: Sphingomyelins -0.01019553
Insecurity regarding the true status of those with a discordant CSF-biomarker
status implies that the class-specific (AD or SCD) samples are heterogeneous. Het-
erogeneity can lead to the dilution of partial correlations and, hence, may hamper
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network extraction [S3.1]. Results on the regulatory signature are, for reasons of
brevity, not included.
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